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ABSTRACT 
Inclusion body hepatitis (IBH) is an economically important fowl adenovirus 
(FAdV) disease of broiler chickens. In Canada, FAdV-8a, FAdV-8b, FAdV-11, FAdV-7 
and FAdV-2 are the prevalent FAdV serotypes. Currently, there is no commercial vaccine 
available in Canada to prevent IBH in broiler chickens. 
The objectives of this study were to develop live, inactivated or subunit FAdV 
vaccines to control IBH and to identify a suitable adjuvant for an inactivated FAdV 
vaccine. In chapter 2, we analyzed the efficacy and safety of live and inactivated bivalent 
FAdV vaccines (FAdV-8b-SK+FAdV-11-1047) against IBH. We demonstrated 
significant immunoprotection of broiler chickens (98 – 100%) (P<0.01) against IBH by 
vaccinating broiler breeders with FAdV-8b-SK+FAdV-11-1047 with either a bivalent 
live vaccine (1x104 TCID50) at 16 weeks of age or a bivalent inactivated vaccine (1x10
6 
TCID50) at 16 and 19 weeks of age. Both the live and inactivated bivalent FAdV vaccines 
induced broad-spectrum protection against all common serotypes of FAdV circulating in 
the Canada. Both the live and inactivated FAdV vaccines were equally efficacious in 
protecting broiler chickens against IBH by passive transfer of maternal antibodies 
(MtAb) from broiler breeders to their broiler progeny.  
In chapter 3, we demonstrated that FAdV-8b-SK adjuvanted with CpG-ODN 
induced a long-lasting humoral immunity similar to inactivated FAdV-8b-SK adjuvanted 
with Emulsigen-D. FAdV-8b-SK adjuvanted with CpG-ODN induced T helper (Th)-1 
and Th-2 type immunity. CpG-ODN as an adjuvant enhanced cytotoxic T-cell memory 
response of FAdV-8b-SK vaccine. 
Propagation of some serotypes of FAdVs are difficult in cell lines. Hence, we 
explored the possibility of developing a subunit FAdV vaccine. In chapter 4, we 
demonstrated significant protection of broiler chickens against IBH by vaccinating their 
broiler breeder parents using a FAdV-8b-SK subunit vaccine [fiber protein or virus-like 
particles (VLPs)]. We also demonstrated that the FAdV-8b-SK fiber and VLPs induce 
strong cytotoxic T-cell responses in the broiler breeders. The results of this study will 
help in designing FAdV control strategies for the prevention of IBH in Canada. 
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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
 
1.1. Introduction 
Inclusion body hepatitis (IBH) is an acute fowl adenovirus (FAdV) disease of 1 to 
5 week old chickens that begins as a sudden increase in mortality, peaking at 4 to 5 days 
post-infection. Enlarged, pale swollen livers exhibiting necrosis and hemorrhages 
characterize the disease. Basophilic intranuclear inclusions in the hepatocytes are the 
main microscopic lesions. Mortality percentage is variable, usually below 10 % but may 
exceed 30% [1]. IBH is prevalent worldwide and its spread is increasing in many 
countries. FAdVs are highly diverse and are categorized into five species (A to E) and 12 
serotypes (-1 to -7, -8a, -8b and -9 to -11) [2]. Most notably, FAdV serotypes FAdV-2, 
FAdV-7, FAdV-8a, FAdV-8b and FAdV-11 are responsible for IBH in chickens [3]. 
Spread of the virus is mainly due to horizontal transmission but vertical transmission 
plays a critical role. Control of IBH has historically been by imposing strict biosecurity 
measures and vaccination of broiler breeder parents with autogenous inactivated 
vaccines. However, their efficacy for protecting against IBH remains undetermined. A 
commercial vaccine is not yet available in Canada; therefore, the aim of this thesis is to 
develop FAdV vaccines (live, inactivated and subunit) to control IBH in Canada and to 
evaluate adjuvants in the inactivated FAdV vaccines. 
 
1.2. History 
In the 1940’s, the first description of intranuclear basophilic inclusion bodies in 
hepatocytes of dogs suffering from infectious canine hepatitis was recorded [4]. Similar 
inclusion bodies were also observed by Olson. (1951) in cases of infectious bronchitis in 
quails leading to a suspicion of a viral etiology [5]. Rowe et al. (1953) described a 
filterable agent from such inclusion bodies in cell culture preparations derived from 
human adenoid tissues [6] and named them “adenovirus” [7]. In 1957, Yates and Fry had 
isolated a new virus from fertile chicken eggs [8] which was then named as chicken 
embryo lethal orphan virus (CELO). Frequent isolation of CELO from eggs and egg-
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based vaccines [9] and its widespread seropositivity in chicken flocks [8, 10] provided an 
impetus to adenoviral research in the 1960s.  
In 1963, Helmboldt and Frazier first described hepatic alterations in broiler flocks 
at 5 weeks of age [11]. Livers were swollen with round edges and stellate hemorrhages.  
They described the histopathological lesions as an “acute hepatic catastrophe” with 90% 
of the parenchyma displaying fatty metamorphosis and Cowdry Type A inclusion bodies 
[11]. Many Canadian researchers have found similar pathological findings and variable 
mortality in broiler chickens in subsequent years [12-14]. Livers were grossly swollen, 
mottled with a reticular pattern similar to Helmboldt and Frazier’s observations. The 
etiological agent was identified in 1973 and named for the first time as FAdV [15]. 
Subsequent cases displaying similar pathological findings of IBH were reported from 
several countries of the world. Today several serotypes of FAdVs (FAdV-2, -7, -8a, -8b 
and -11) which cause IBH have been identified [1].  
 
1.3. Adenoviridae taxonomy 
Adenoviruses have diverse vertebrate host range, which include mammals, birds, 
reptiles, amphibians and fish [2, 16]. Historically, the family Adenoviridae has been 
divided two major genera, Mastadenovirus and Aviadenovirus, which included viruses of 
mammals and birds, respectively [17]. Adenoviruses of birds were further categorized 
into three separate groups: groups I, II and III. Groups II and III contained poultry 
adenoviruses which were serologically unrelated to the group I [18] and were referred as 
unconventional poultry adenoviruses. 
In 2011, the International Committee on Taxonomy of Viruses (ICTV) re-
classified the family Adenoviridae into five genera; Mastadenovirus, Atadenovirus, 
Siadenovirus, Icthadenovirus and Aviadenovirus based on the molecular criteria reviewed 
in their 9th report of ICTV [2]. The new classification of the family Adenoviridae 
categorized the unconventional poultry adenoviruses of group II as well as the 
unconventional members of the genus Mastadenovirus into genera Siadenovirus and 
members of group III poultry adenoviruses into the genus Atadenovirus. While the 
members of the genus Siadenovirus only affect amphibians and birds, members of the 
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genus Atadenovirus have the most divergent host range among all known adenovirus 
genera [16]. It is hypothesized that these viruses must have had undergone a host switch 
during their evolution [19-21].  
 
1.3.1. Mastadenovirus 
These viruses affect a wide range of mammalian species, such as primates, cattle, 
dogs, horses, pigs, sheep, mice, tree shrews, bats and human beings [2, 22]. The host 
range was also extended to mammalian fish [23]. The most significant species within this 
genus are human adenoviruses. There are seven species and 51 serotypes of human 
adenoviruses (HAdVs) identified so far [24]. Many of these are the etiologic agents of 
diseases such as pneumonia, gastroenteritis, conjunctivitis, hepatitis and myocarditis 
(especially in children [25, 26]) and fatal pneumonia (in military recruits [27]). Besides 
being a primary pathogen, they are identified as a potential source of nosocomial 
infections in immunocompromised children [28-30]. Other than human beings, the most 
notable adenoviral diseases of veterinary importance are infectious canine hepatitis and 
tracheobronchitis associated with canine adenovirus-1 and -2 infection in puppies [31, 
32].  
 
1.3.2. Atadenovirus 
Atadenoviruses are named so because of the exceptionally high adenine and 
thymine content of their genome, 57 to 66.4%, which is highest among all known 
adenoviruses [19, 33]. In contrast to other genera of adenoviruses, this genus has broad 
hosts ranging from reptiles, mammals, marsupials and birds [19]. Of the various species 
known, only Duck Adenovirus-1 of the species Duck Adenovirus-A causes an 
economically important disease in chickens. 
 
1.3.3. Siadenovirus 
These viruses have the smallest genomic size (26,163 bp to 26,282 bp) among 
adenoviruses [2]. They are named as Siadenovirus as they possess a unique protein 
‘sialidase’ encoded by a gene located on the left end of the genome [33]. Members of this 
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genus only affect amphibians and birds. There are five officially recognized species 
reviewed by Harrach et al. (2011) [2]. Turkey adenovirus-3 of the species Turkey 
Adenovirus-A is a significant pathogen of poultry.  
 
1.3.4. Icthadenovirus 
Icthadenoviruses only affect fish (white sturgeon) and are non-pathogenic. White 
Sturgeon Adenoviruses have the largest known adenovirus genome (48,395 bp) [2, 34]. 
 
1.3.5. Aviadenovirus 
Members of the genus Aviadenovirus were traditionally referred as FAdVs. There 
are many other recognized and proposed adenovirus species in this genus that affect birds 
other than chickens, such as; falcons, goose, turkeys, ducks, pigeons and parrots [1]. 
Adenoviruses of ducks, pigeons, parrots and turkeys all still await official recognition in 
the genus [2]. There are eight officially accepted species in this genus including Falcon 
Adenovirus-A, Goose Adenovirus-A, Turkey Adenovirus-B and FAdV (A to E).  
 
1.3.5.1. Fowl Adenoviruses 
FAdVs are economically significant pathogens of domestic poultry. They cause 
diseases such as IBH, hepatitis-hydropericardium syndrome (HHS) and gizzard erosion 
and ulceration in broilers and layers as well as quail bronchitis in quails [1, 18]. There is 
huge diversity among FAdVs. Historically, were classified into five genotypes, A to E, 
based on polymerase chain reaction (PCR) and restriction fragment length polymorphism 
(RFLP) [35-37] and into 12 serotypes (-1 to -7, -8a, -8b and -9 to -11) based on serum 
neutralization profiles [22, 38, 39]. In 2011, the ICTV has accepted the previously 
classified genotypes (A to E) as the five official species of FAdVs Table 1-1.  
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Table 1-1: List of genotypes, serotypes and strains of fowl adenoviruses.ICTV. 
 
Species Strain Serotypes 
A CELO, 112, QBV, Ote, H1 FAdV-1 
B 340, TR-22, Tipton, M2 FAdV-5 
C 506, J2, KR5, H2 FAdV-4 
D GAL-1, 685, SR48, H3, P7 FAdV-2 
 SR48, 75, H5 FAdV-3 
 A2, 90, CFA19 FAdV-9 
 380, UF71 FAdV-11 
E YT36, x-11a like, 122 FAdV-6, FAdV-7 
 TR59, T8-A, CFA40A FAdV-8a 
 764, b3, VRI-33 FAdV-8b 
Information adapted from 9th report of ICTV [2] and Group I Adenovirus infections (Diseases of Poultry, 
13th Ed) [1]. 
 
1.4. Adenovirus structure 
Adenoviruses are non-enveloped double stranded (ds) DNA viruses of icosahedral 
symmetry varying between 70 and 90 nm in diameter. A mature virion comprises of an 
outer capsid and a central core [40]. The adenovirus capsid consists of major structural 
proteins (designated as II, III and IV) and minor structural proteins (IIIa, VI, VII, VIII 
and IX). The adenoviral core comprises of the viral genome and its associated proteins; 
V, VII, mu-protein, and terminal protein (TP) [40-42].  
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Figure 1-1: Structural proteins associated with the adenovirus capsid. Courtesy: 
Biochemistry Journal. 2010. 431(3):321-36. Reproduced with permission of the 
publisher. 
 
1.4.1. Major capsid proteins   
Hexon (II), penton (III) and fiber (IV) proteins are the major capsid proteins of 
the adenovirus capsid. Among these proteins, the hexon protein is the most abundant 
component [40]. Two hundred and forty hexon molecules are arranged in groups of 12 to 
form 20 triangular faces. Nine central hexon molecules within a triangular face contribute 
to the formation of the group-of-nine (GON) configuration (Figure 1-2) and are glued 
together by protein IX.  
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Figure 1-2: Arrangements of hexon trimmers in a triangular face. Hexon (light blue), 
penton (yellow) and fiber (dark blue) proteins make the major portion of adenovirus 
capsid. The inset shows the GON arrangement of the hexon trimmers in a triangular face, 
as well as the arrangement of minor structural proteins IIIa, VI, VIII and IX in relation to 
hexamers. Courtesy: Viruses. 2012. 4:847-877. Reproduced with  permission of the 
publisher. 
 
The remaining three hexon units at the corners of each triangular face contribute 
to the formation of the group-of-six (GOS) configuration. A GOS configuration consists 
of hexamer units from adjacent triangular faces around a central penton ring at each 
vertex of the virion) [41]. These hexon units are called the peripentonal-hexon. The 
components of the GOS are linked to each other by polypeptide IIIa. Another 
polypeptide, VI, is located beneath the vertex which bridges hexon proteins to dsDNA 
[42]. The second most abundant protein in the capsid is the penton ring. It has a 
pentameric structure and is present at each vertex where it forms a non-covalent complex 
with the fiber protein. The adenovirus fiber protein comprises of a head, shaft and a tail. 
The head of the fiber protein carries sites for host cell receptors. The entire assembly 
(fiber and penton proteins) is required for efficient entry of the virus into the host cell 
[43].  
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Figure 1-3: GOS configuration. Arrangements of peripentonal-hexon molecules 
(uncoloured) around the penton ring (blue) at the vertex forming GOS configuration. 
Adapted from Viruses. 2012. 4:847-877. 
 
1.4.2. Minor capsid proteins 
Polypeptides IIIa, VI, VIII and IX are the minor structural proteins of the 
adenovirus capsid. These proteins stabilize the capsid and are critical for the biological 
properties of adenoviruses including temperature sensitivity, infectivity, nuclear import 
of hexon proteins, capsid assembly, genome packaging and maturation of the virus [42].  
Most of the structural proteins are evolutionarily conserved amongst 
adenoviruses. A few proteins either vary in their number or are genus-specific to 
adenoviruses. Members of the genus Aviadenovirus possess two fibers at the vertex [43] 
whereas; only a few members of the genus Mastadenovirus possess two fibers at the 
vertices (subgroup-F HAdV and simian adenoviruses). Members of the Siadenovirus and 
Atadenovirus genus possess only one fiber per vertex. Lizard adenovirus-2, which is a 
new member of the genus Atadenovirus possess three fibers on one to two vertices and 
two fibers at the remainder of the vertices [16]. Besides the adenovirus fiber, 
polypeptides V and IX are only present in the members of the genus Mastadenovirus [2].  
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1.4.3. Core proteins 
Core proteins lie within the mature adenovirus virion along with the viral genome. 
These proteins include polypeptides V and VII, mu-protein, TP, DNA-binding-protein 
(DBP) and adenovirus protease (ADP). These proteins unwind the viral genome (i.e. 
DBP) and initiate genome replication (i.e. TP). They also assist in tightly packaging the 
viral genome inside the capsid shell (polypeptides V and VII and mu-protein). In 
addition, they also aid in virion maturation (polypeptide VII) and bridging the core to the 
capsid proteins (polypeptide V) [44, 45].  
 
1.4.4. Adenovirus genome 
The adenovirus genome is a linear dsDNA molecule. Each strand of it is non-
covalently linked to TP at its 5’ end [44]. The genome size ranges from 26,163 bp 
(Atadenovirus) to as large as 48,395 bp (Icthadenovirus) [2]. In general, the genome is 
organized into several functional regions: inverted terminal repeats (ITR) on each side of 
the genome, early regions, late regions and many other open reading frames (ORFs) that 
do not fall in these regions. The adenovirus genome contains evolutionary conserved ITR 
on both ends. The rest of the genome is divided into different transcription units: early 
regions (designated as E1A, E1B, E2A, E2B, E3 and E4 genes), delayed early genes (IX, 
IVa2 and a few E2A genes), late regions (designated as L1, L2, L3, L4 and L5) and some 
other transcriptional units such as viral encoded RNA (VA-RNA) genes (Figure 1-4). 
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Figure 1-4: Adenovirus genome organization. Forward reading strand encodes the 
E1A, E1B, IX, major late proteins, VA-RNA and E3 units. The reverse strand contains 
the E4, E2A, E2B and IVa2 genes, (Mastadenovirus; HAdV). Black arrows = early 
genes, blue arrows = intermediate genes, green arrows = late genes, red arrow = viral 
encoded RNA I and II. Courtesy: Biochemistry Journal. 2010. 431(3):321-36. 
Reproduced with permission of the publisher. 
 
Besides having conserved regions, striking differences exist in the genomic 
organization of members among different adenovirus genera. The differences mainly 
occur by the presence or absence of early transcriptional units (E1, E3 and E4) or the 
presence of genus-specific genes (Table 1-2). 
  
 
1
1
 
Table 1-2: Genomic differences among the genera of the Adenoviridae family 
The information is adapted from the 9th report of ICTV [2]. NA = Information not available. – denotes absence of the genomic region and + denotes 
presence of genomic region in the genome of adenoviruses. 
 
  
Genomic region Mastadenovirus Aviadenovirus Siadenovirus Atadenovirus Icthadenovirus 
E1A/B  + - - + (E1B) NA 
E2A/B  + + + + NA 
E3 + - - - NA 
E4 + - - - NA 
V + - - - NA 
IX + - - - NA 
GAM-1 - + - - NA 
MDV-gp - + - - NA 
dUTPase + (right end) + (left end) - - NA 
LH1-3  - - - + NA 
P32K - - + + NA 
Silidase - - + - NA 
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All regions are present in the genus Mastadenovirus, whereas members of  
Aviadenovirus and Siadenovirus lack all the E1, E3 and E4 regions [2]. Members of the 
genus Atadenovirus only possess the E1B region in their genome in addition to the E2 
and E4 regions. Proteins encoded by the E1A region of adenoviruses are essential for the 
transactivation of genes from E2, E3, E4 and the late regions of the genome [46]. Besides 
transactivation of the genes, the E1 gene products (proteins) are capable of initiating 
cellular transformation along with the proteins from the E1B region [46, 47]. Similar to 
E1 gene, E4 ORF-1 gene products also exhibit tumorigenic activity. Proteins encoded by 
the genes of the E3 region possess immunomodulation activity [48].  
In addition to early genes, each adenovirus genus has unique genus specific-
genes. These include genes V and IX in the genus Mastadenovirus, gene encoding 
protein sialidase in the genus Siadenovirus, genes LH1-LH3 and p32K in the genus 
Atadenovirus and genes GAM-1 and Marek’s disease virus (MDV)-gp in the genus 
Aviadenovirus. Gene relocalization and duplication are other characteristic features of of 
genera Aviadenovirus and Atadenovirus [2].  
 
1.5. Cell infection and replication 
 Adenoviruses affect a variety of epithelial cells [48, 49],  endothelial cells [50] as 
well as cells of the monocytes/macrophage system [50, 51]. Adenovirus infections begin 
with preliminary interactions between the adenovirus fiber-knob and the host cell 
receptor (Figure 1-5), most commonly the coxsackie-adenovirus-receptor (CAR) [52-54]. 
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Figure 1-5: The cell entry pathway of adenovirus. Receptor-mediated endocytosis into 
the clathrin-coated pit (steps 1 and 2), the formation of the endosome (step 3), the release 
of dismantled virus from the endosome (step 4), cytoplasmic transport through dyenine 
on microtubules (step 5) and nuclear import into the nucleus (step 6). Courtesy: Virology. 
2009. 384(2):380-388. Reproduced with permission of the publisher. 
 
Numerous other cellular receptors, such as heparin-sulfate glycosaminoglycans 
(GAGs), CD46, CD80, CD86, sialic acid and major histocompatibility complex (MHC) 
molecules have been identified. These have been found to allow HAdVs to enter different 
cell types [55]. Following the initial interaction, a secondary interaction of the arginine-
glutamine-aspartic acid (RGD) motif of the penton ring occurs with the αβ type integrin 
receptor. The adenovirus becomes internalize into a clathrin-coated invagination 
(endosome) of the cell membrane [56]. Upon acidification of the endosome, the vertex of 
the virus dismantles and releases the core of the adenovirus [57]. Minor structural protein 
VI is released from the dismantled virion causes endosome membrane lysis and 
subsequent release of the viral core into the cytoplasm [58].  
The core of the adenovirus is carried to the nuclear-pore complex on a 
microtubule network with the help of a dynein protein [59]. Various interactions between 
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the shuttle proteins and the nuclear-pore complex proteins finally deliver the adenovirus 
core into the nucleus [60]. Within the nucleus, early genes transcribe first and their 
messenger RNAs (mRNA) are exported to the cytoplasm for protein synthesis. These 
proteins regulate the cell cycle, modulate host immune responses, transactivate other 
genes and are responsible for viral DNA replication.  
Adenovirus genome replication is protein-primed in nature. It begins at the origin 
of replication (ORI) in the ITR at both of the genomic ends. DNA replication is initiated 
at the 3’ end of the antisense strand by a complex interplay between the precursor 
terminal protein (pTP), DNA polymerase, DBP, and several nuclear factors [44]. Early 
gene (E1A) products transactivate the major late promoters (MLP), which then initiate 
the transcription of genes from the late regions [61]. Thereafter, the mRNA is exported to 
the cytoplasm for protein synthesis. These proteins include major capsid proteins and 
genome encapsidation proteins. Ahi et al. (2016) comprehensively reviewed the events of 
the capsid assembly and genome packaging in detail [45]. Briefly, following the nuclear 
import of structural proteins (II, III, IV, IIIa, VI, VIII, IX) and encapsidation proteins, 
capsid assembly occurs in the nucleus. The adenoviral genome is encapsidated in a polar 
fashion following the interaction of encapsidation proteins (IVa2, 52/55K, 33K, 22K) 
with the packaging domain at the left end of the genome and various other viral and 
cellular proteins. Adenovirus protease removes the scaffold proteins once the genome is 
packaged inside the virus core and also cleaves the structural proteins to form the 
infectious virus, which is then released by lysis of the cells. 
 
1.6. Immune response to FAdV 
Immunity to infectious agents broadly consists of innate immunity (immediate and 
non-specific) and adaptive immunity (pathogen-specific) which develops over time and is 
capable of clearing the pathogen from the host body [62]. 
 
1.6.1. Innate immune response 
Innate immunity comes into play within minutes to hours, containing the 
microbes and limiting their spread.  Innate immune response occurs in many ways such 
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as enzymes (lysozymes), antimicrobial peptides (α and β-defensins), innate immune cells 
(neutrophils, eosinophils, macrophages, natural killer (NK) cells and dendritic cells (DC)) 
and humoral components (complement systems) including anatomic and physiological 
barriers [63]. Innate immune cells harbor an array of evolutionarily conserved pattern 
recognition receptors (PRRs), which recognize pathogen-specific molecular patterns 
(PAMPs). The PRRs includes a repertoire of extracellular and intracellular receptors [62], 
which upon interaction with PAMPs results in the activation of many downstream 
pathways. Cellular activation results in the secretion of antimicrobial substances 
(enzymes and peptides) to kill the pathogen, releasing cytokines and chemokines to 
attract more inflammatory cells (neutrophils, macrophages), antigen-presenting cells 
(APCs) and subsequently activation of the adaptive immune response.  
 Innate immune system in mammals responds to viral pathogens by recognizing 
viral PAMPs by PRRs. Viral PAMPs mainly includes viral proteins, viral DNA, single-
stranded (ss) RNA, dsRNA and RNA with 5’ phosphatases ends [64]. Antiviral innate 
immune responses occur mainly through toll-like receptors (TLR-2, TLR-3, TLR-7, and 
TLR-9), nuclear organization (NOD) like receptors (NLRs), retinoic-acid inducible gene-
I (RIG-I) like receptors and DNA dependent interferon (IFN) regulated factors (DAI) 
[64-66]. Chickens share functional similarities with mammalian immune systems in 
regard to pathogen sensing through innate immune receptors such as TLRs (TLR-3, TLR-
4 and TLR-7), retinoic acid inducible gene (RIG)-1-like receptors [Melanoma 
Differentiation Associated protein-5 (MDA-5) and Laboratory of Genetics and 
Physiology-2] and NLR (NOD-1). However, there are some striking differences in 
chickens. Some of the PPRs are absent in chickens (e.g., TLR-9, RIG-1, NOD-1), while 
others are either duplicated (chTLR-1a, chTLR-1b and chTLR-2a, chTLR-2b) or are 
unique to chickens (chTLR-15 and chTLR-21) [67]. 
Adenovirus infections in mammals activate an array of immune mechanisms. 
Adenovirus capsid proteins, viral DNA and VA-RNA are the chief triggers of innate 
immunity [68]. Adenovirus-specific cellular receptors upon recognition of the adenovirus 
capsid proteins triggers a downstream activation of phosphoinositol kinase [69-71] or 
mitogen-activated protein kinase pathways [68, 72]. These pathways lead to nuclear 
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import of nuclear factor kappa-β (NF-kβ) or activation of interferon regulatory factors 
(IRF). The NF-kβ and IRF pathways activate genes of inflammatory cytokines, such as 
IL-1, IL-6, IL-8 and IL-18, tumor necrosis factor (TNF)-α, monocyte inflammatory 
protein (MIP)-1α and MIP-2, RANTES (regulated on activation T-cell excreted and 
secreted), CXC-type chemokines and IFN-γ [68, 73, 74]. 
Within infected cells, the naked adenoviral DNA triggers DAI or NLRs pathways. 
Within the endosome, it stimulates the TLR-9 mediated pathway [68]. TLR-9 leads to the 
production of inflammatory cytokines and type-1 IFNs by the myeloid differentiation 
factor-88 (MyD88) pathway and IRF-7 pathways, respectively [75]. DAI induces type-1 
IFNs by activating the IRF-7 pathway by a different set of adapter molecules such as 
TANK-binding kinase/Inhibitors of IκB kinase [74]. In addition to the TLR-9 or DAI 
dependent pathways, NLR mediated DNA sensing leads to the recruitment of apoptosis 
spec protein and caspase-1 protein in the cytosol to form an inflammosome [76]. The 
inflammosome cleaves the preformed IL-1 and IL-18 to their active forms that are 
subsequently secreted form the cells [77]. IL-1 acts in an autocrine manner on the IL-1R 
receptor to amplify its production through the MyD88 pathway [68]. The type of pathway 
may vary depending on cell type. For instance, TLR-9 mediates responses in the major 
pathway in the plasmacytoid dendritic cell [68, 75]. In contrast, the DAI pathway 
operates chiefly in the myeloid dendritic cells, macrophages or fibroblast [74].  
Chen et al. (2013) comprehensively reviewed the mechanisms of antiviral innate 
immune response in birds [67]. Viral nucleic acids such as ssRNA and dsRNA are sensed 
by TLR-3 and TLR-7 as in mammals; however, cytosine phosphodiester guanine 
oligodeoxynucleotide (CpG-ODN) is sensed by TLR-21 instead of TLR-9 in the 
endosomal compartment. TLR-3 or TLR-7 operate through NF-kβ and IRF-3/7 pathways 
to induce inflammatory cytokines and a type-1 IFN response, while TLR-21 only induces 
inflammatory cytokines through the NF-kβ pathway. Similar responses are induced by 
long dsDNA, dsRNA or short 5’ triple phosphate dsRNA in the cytoplasmic 
compartments through MDA-5 or RIG-I receptors through the NF-kβ and IRF-3/7 
pathways [67, 78, 79]. Some experimental studies in chickens show that FAdV infections 
result in the induction of type-1 IFNs (IFN-α), IL-12 and IL-18 [80-82] and down-
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regulate IL-10 and IL-8 expression [80, 81].Further studies are needed to compare 
cytokine responses of FAdV infections and chickens vaccinated with FAdV vaccines.  
Innate immune responses lead to the recruitment of inflammatory cells, 
macrophages, and antigen presenting cells APCs. These cells engulf the foreign 
infectious agent, secrete cytokines and chemokines and stimulate adaptive immunity (T-
cell help) by the MHC-I and MHC-II pathways. This subsequently leads to the generation 
of pathogen-specific cytotoxic T-cells and antiviral antibodies.  
 
1.6.2. Adaptive immune response 
Similar to mammals, the adaptive immune response in chickens has two arms, 
cellular and humoral, which responds to viral pathogens by inducing cytotoxic T-cell 
responses and antibody responses [83, 84].  
Cell-mediated immunity (CMI) consist of CD4+ (helper T-cells) and CD8+ 
(cytotoxic T-cells) which is dominated by IFN- responses [84, 85] leading to increased 
activation of macrophages and NK-cells (intracellular immunity). Chickens mount CMI 
responses to a variety of intracellular pathogens [86, 87]. The role of CMI is critical in 
the clearance of virus infected cells which is evident by experimental immunosuppression 
induced by chemical agents [88] or infectious agents [89, 90]. A few reports have 
documented the dynamics of CMI against FAdVs [91, 92]. However, more research is 
warranted in this area in the future. 
Humoral immunity is dominated by the increased expression of cytokines like IL-
4, IL-10 and antibody production (extracellular immunity) by plasma cells (differentiated 
B lymphocytes) [90]. Unlike mammals, who have five types of antibodies, birds have 
three principle antibody types, immunoglobulin (Ig) M, IgY (mammalian analog of IgG), 
and IgA. IgM is the primary antibody produced upon infection and is switched by IgY as 
the immune response matures [93]. These two are important in protecting internal organs 
from pathogens. IgA plays an important role in protecting from pathogens at mucosal 
surfaces [86].  
Major capsid proteins of the virus are the major targets of adaptive immunity. 
Adenoviral major capsid proteins (fiber, penton and hexon) are capable of eliciting both 
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cellular [94, 95] and antibody-mediated immunity [96-98]. Among the three capsid 
proteins, hexon is the main constituent of the capsid [99] and, therefore, elicits the 
highest level of cellular [94, 95] or antibody response [100, 101]. Similar to HAdV, 
FAdV hexon proteins are the principle component of the capsid, which induce type-
specific neutralizing antibodies [1]. The hexon protein is a complex trimeric of proteins, 
which is comprised of four loop structures. Of these loops, loops two and four contains 
group and type-specific epitopes. Besides antibody responses to hexon proteins, a lower 
fraction of antibodies are produced against the HAdV fiber and penton proteins [101]. 
Like HAdVs, the neutralizing potential of antifiber and antipenton antibodies of FAdVs 
is currently doubtful. The humoral arm of the adaptive immune system is stimulated to 
hyperimmunize the parents to protect their progeny against viral diseases by maternal 
antibodies [102]. 
 
1.7. Adenovirus as vaccine vectors 
Adenoviruses effectively deliver genes to cells due to their predilection to a 
variety of cells, their enormous foreign DNA carrying capacity (up to 36 kb), ease of 
mass production, safety, efficacy, stability and, more importantly, their inability to 
integrate into the host genome [103-106]. HAdV-2 and HAdV-5 are under investigation 
as gene delivery vehicles to treat genetic defects, to compensate immunodeficiency 
diseases, as a vaccine vectors and as a modality for the treatment of cancers [103, 106-
109].  
Danthinne and Imperiale (2000) have reviewed the advantages and disadvantages 
of adenovirus vectors in detail [110]. Three generations of vectors are available based on 
the genomic regions deleted from the virus. For example, primary adenovirus vectors 
lack the E1 and E3 regions, whereas secondary vectors also lack E2 and E4 in addition to 
previously mentioned genes. The tertiary vectors are called gutless vectors as all or most 
of the genomic regions are removed, except the ITRs and cis-complementing packaging 
sequence [110]. Unfortunately, therapeutic gene expression is ephemeral with adenovirus 
vectors due to wide-spread pre-existing anti-vector antibodies (HAdV-5) among people 
[98, 100], or quick vector clearance by strong host anti-vector specific CD8+ cytotoxic T-
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cell responses [101, 103, 111]. Researchers have manipulated the adenovirus genome by 
making chimeras with non-human primate adenoviruses to elude pre-existing 
antiadenoviral antibodies [103, 112, 113]. Innovative methods like engineering fiber or 
hexon proteins to make chimeric proteins have been investigated [114]. Moreover, other 
options like the use of less prevalent adenovirus serotypes [115], targeting mucosal 
delivery [116], microencapsulation [117] and generating gene deletion mutants [106] 
have also been utilized. 
Interestingly, non-human adenoviruses (bovine, porcine, canine, ovine, simian 
and FAdVs) were preferred for many reasons such as the lack of antibodies in the human 
population, potentially low pathogenicity in their hosts and similarity in the structural and 
genomic organization to the HAdVs [103, 118, 119]. These viruses are under 
investigation to develop potential future vaccine vectors. Besides human medicine, 
vectored vaccines have also become popular in veterinary medicine to protect animal 
health [120]. Olasumbo et al. (2013) reviewed numerous animal adenovirus vectored 
vaccines developed to protect animal health [121], such as Canine Adenovirus-2 
expressing rabies virus glycoprotein, HAdV-5 expressing hemagglutination of avian 
influenza virus [122], Bovine Adenovirus-3 expressing group-D antigens of herpes virus 
[123] and many other viruses [121]. 
Unprecedented growth occurred in the poultry vectored vaccine industry in the 
last decade. Meeusen et al. (2007) have enumerated various viral vectored vaccines 
licensed in the veterinary industry [120]. MDV vectored vaccines have pioneered poultry 
vector vaccine industry. Its genome has been used in a number of chicken viruses such as 
infectious bursal disease virus (IBDV) [124], Newcastle disease virus (NDV), avian 
influenza virus [125] and infectious laryngotracheitis virus [126]. A recent study has also 
documented the development of a MDV-vectored avian leucosis virus subgroup-J 
vaccine [127]. Likewise, other promising vectored vaccines of avian origin viruses 
include; avian poxvirus and canary poxvirus [120]. In recent years, chicken viruses like 
NDV [128, 129] and FAdVs [121] are under investigation to develop vaccine vectors. 
Numerous serotypes of FAdVs are being developed as vaccine vectors to deliver 
foreign DNA to protect poultry health against various pathogens [121]. Unlike HAdV 
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vectors, they are still in the preliminary stages of development [130]. It had become 
possible to manipulate FAdVs and engineer them to develop vectors because of the 
availability of their full genome sequences (FAdV-1, FAdV-8, FAdV-9 and FAdV-10) 
[131-134], and comparative genomic analysis with the members of the genus 
Mastadenovirus [2]. FAdV-1, FAdV-8 and FAdV-10 are first-generation replication 
competent FAdV vectors [133, 135-137] used for the development of FAdV vectored 
IBDV vaccines carrying the viral protein-2 gene. These vectored vaccines have shown 
protective efficacy against IBDV in animal experiments. FAdV-1, FAdV-8, FAdV-10 
and FAdV-9 are currently in the experimental stages for the generation of a vaccine 
vector [80]. More recently, another serotype of FAdV (FAdV-4) is under investigation 
for developing a vaccine vector owing to its minimum host pathology [81]. In addition to 
their use for vectored vaccine development for poultry pathogens, they are a suitable 
candidate to make vectors for gene therapy in human beings owing to their defective 
replication [138] or non-infectiousness in many human origin cell lines [139, 140]. CELO 
virus has been successfully tested to express human interleukin (IL) genes in embryos as 
well as for gene therapy for cancers [139, 141], which exemplifies their scope as potential 
vectors for human medicine. 
 
1.7.1. Avian adeno-associated viruses 
Apart from the mammalian and avian adenoviruses (now called as FAdVs), Adeno-
associated viruses (AAVs) have become popular gene delivery vehicles and vaccine 
vectors. AAVs are defective parvoviruses, which belong to the genus Dependovirus of 
family Parvoviridae [142]. AAVs are unique as they require helper functions from 
adenovirus (genes: E1a E1b, E4 and VA-RNA) or herpes virus (genes: DNA polymerase 
and helicase) for productive infection (known as lytic phase) [142]. Helper viruses also 
suppress cellular functions and create a milieu suitable for AAV replication. In the 
absence of help, AAVs establish latency in the cells by site specific integration in the host 
genome (known as lysogenic phase) [143]. Their non-pathogenic nature, ability to 
replicate in both dividing and non-dividing cells, large gene inserts carrying capacity and 
surviving the host immune response make them suitable agents for gene delivery vehicles 
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[142]. AAVs have been identified from human beings, primates and avian species [142, 
144]. Avian adeno-associated viruses (AAAVs) are ubiquitous in the chicken population 
and are often isolated from healthy chickens [144]. They readily grow in chicken 
embryos and the cells of chicken origin when coinfected with FAdVs. Bauer et al. (1986) 
have shown FAdV serotypes 1, 5 and 8 promote the productive infection of AAAVs in 
chicken kidney cells and chicken fibroblast cells [145, 146] . While FAdVs impart helper 
function for AAAV infection, it has been also demonstrated that AAAVs reduce the 
virulence of FAdVs (Timpton strain) in chicks coinfected with FAdVs in a dose 
dependent manner [147]. Due to lack of pathogenicity in chickens [144, 148] and 
properties similar to mammalian AAVs, AAAVs are being developed to deliver gene 
based vaccines against economically significant chicken pathogens [148, 149]. 
 
1.8. Oncogenicity of Adenoviruses 
Most of the adenoviruses do not cause cancer in humans or animals [56, 150] but 
are capable of transforming cells in non-permissive hosts [151]. HAdVs of subgroup A 
(HAdV-12) and C (HAdV-2 and HAdV-5) cause undifferentiated sarcomas in rodents 
[152], whereas, HAdV-9 of subgroup D has been implicated as a cause of mammary 
gland carcinoma [153] or fibroadenomas in rats [154]. It is experimentally proven that 
proteins encoded by the genes of E1A and E1B transcriptional units of HAdV-2, HAdV-
5, and HAdV-12 transform cells by inactivating retinoblastoma and p53 suppressor 
proteins [46, 155-157]. In contrast to the members of subgroup A and B, HAdV-9 
transform cells presumably by a hit and run mechanism [158] and this effect is attributed 
to a protein encoded by ORF-1 of E4 transcriptional-unit [153]. Since E1A and E1B 
transcripts/proteins share common pathways of cellular transformation with the 
SV40TAg protein of simian virus 40 and early-6/7 proteins of papilloma viruses, these 
viruses are considered as an important model to study viral carcinogenesis [151, 157]. 
Among FAdVs, only the CELO virus has been associated with the development 
of sarcomas in golden Syrian hamsters [159, 160]. Proteins encoded by gene GAM-1 and 
ORF-22 of CELO virus inactivates the retinoblastoma protein [160] similar to HAdVs to 
transform cells. No reports are available on other FAdVs effects on carcinogenesis. 
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1.9. Common diseases in poultry 
FAdVs are ubiquitous in chicken populations as evident by serological surveys 
and it is not surprising to isolate them from healthy or sub-clinically infected birds [1, 
18]. FAdVs cause a variety of conditions in birds. These include pulmonary congestion, 
proventriculitis, gizzard-erosions, pancreatitis, hepatitis and immunosuppression in 
chickens [161-165], bronchitis in quails [166, 167], tracheitis and hepatitis in turkeys 
[168, 169], hepatitis and pancreatitis in pigeons [170, 171], pancreatitis in guinea fowl 
[172], hepatitis in raptors [173], quails [174, 175], parrots [176], kestrels [177], tawny 
frogmouths [178], geese [179] and ducks [180]. Some of the common economically 
important diseases caused by adenoviruses in poultry are hemorrhagic enteritis, egg drop 
syndrome, quail bronchitis, hepatitis hydropericardium syndrome (HHS), gizzard 
erosions and ulcerations and IBH. 
 
1.9.1.  Hemorrhagic enteritis 
Turkey Adenovirus-3 of the species Turkey Adenovirus-A is a significant 
pathogen of poultry. It causes hemorrhagic enteritis in 2 to 8 week old turkeys. 
Hemorrhagic enteritis is characterized by necrohemorrhagic enteritis and necrotic 
splenitis accompanied with high mortality (1-60%). Two serologically indistinct viruses 
from hemorrhagic enteritis virus cause marble spleen disease in pheasants and 
splenomegaly in chickens [18]. They are known as marble spleen disease virus and avian 
splenomegaly virus, respectively. 
 
1.9.2. Egg drop syndrome 
Of the various species known, only Duck Adenovirus-1 of the species Duck 
Adenovirus-A causes an economically important disease in chickens. Duck Adenovirus-1 
cause sudden egg drop syndrome in laying hens [18, 181] and quails [182, 183]. The eggs 
shape and size distort considerably. The eggshells lose color (in case of colored shell 
eggs), become soft or even fail to form. The internal egg quality remains unaffected. The 
deterioration of egg shell quality is directly related to destruction of the shell glands by 
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virus replication. The lesions are characterized histologically by inflammation, edema, 
loosening of shell glands and infiltration of heterophils and lymphocytes. The virus is 
excreted in the eggs and in the reproductive tract secretions. Vertical transmission is the 
main mode of virus spread among chicken flocks. The disease is prevented by 
vaccination of pullets with inactivated egg drop syndrome vaccine. 
 
1.9.3. Quail bronchitis 
 FAdV-1 causes a highly fatal contagious respiratory infection in 2 to 3 week old 
bobwhite quails [184] and is known as quail bronchitis. Respiratory signs, swollen 
sinuses, expectoration of mucus, asphyxiation and high mortality (up to 50%) in 
susceptible flocks are characteristic features of the disease [167, 184]. Histologically, 
necrosis of respiratory epithelium of the trachea, bronchi and lungs, necrosis of 
hepatocytes, splenocytes, and bursal epithelium, with the formation of basophilic 
intranuclear inclusions in dead and degenerating epithelial cells are the characteristic 
lesions [166, 167, 174]. Quail bronchitis was first described by Olson in the 1950s, 
however, the etiologic agent could not be identified at that time [5]. The disease is 
prevalent in most quail-rearing areas of the world. Quail bronchitis is devastating to quail 
farming and needs attention to prevent infection and subsequent losses. 
 
1.9.4. Hepatitis Hydropericardium Syndrome 
After the discovery of FAdV causing IBH, another peculiar disease resembling 
IBH was reported in Angara Goth, Pakistan in 1988 [185]. HHS is an acute FAdV 
(FAdV-4) disease of 3 to 6 week old broiler chickens. Very high mortality (20-80%), 
development of fluid-filled pericardium (hydropericardium), pulmonary congestion, 
nephritis and urates deposits in kidneys [162, 186-188] are the striking features of the 
disease. HHS causes comparatively higher mortality than IBH and the affected chickens 
develop hydropericardium, pulmonary congestion and nephritis in addition to hepatitis 
[185, 189, 190]. Suspicions of an adenovirus etiology [191] were noted and later 
confirmed as FAdV-4. After its first description, the disease was reported from many 
areas; India, China, Korea, Japan, Russia, Middle East, Europe, South America and 
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Mexico [18, 162, 180, 189, 192-194]. The disease has never occurred in Australia and 
New Zealand due to their geographical separations. In North America, the disease is 
highly prevalent in Mexico [189], but has never been reported in the USA. Although the 
disease is not present in Canada, FAdV-4 has been isolated in Ontario [195]. However, 
this serotype was apathogenic to chickens [81]. Experimental studies failed to reproduce 
disease due to non-pathogenic nature of the virus [81]. The disease has emerging and 
remerging status. This may be due to its increasing spread to countries of non-prevalence 
and failure of vaccine preparations in the countries of prevalence [162, 186]. HHS is of 
great economic significance in the countries of its prevalence and perceived as a threat to 
broiler industry.  
 
1.9.5. Gizzard erosions and ulcerations 
Gizzard erosions and ulcerations are frequently reported in broiler chickens due to 
chemical or fungal causes [196]. However, Tanimura et al. (1993) first reported the 
involvement of FAdV in cases of pancreatitis and gizzard erosions in 10 week old layers 
in Japan [197]. Later in 2001, Abe et al. (2001) identified a group 1 avian adenovirus 
(now designated as FAdV-1 of species A) from cases of gizzard erosions [198]. A few 
other reports have also described FAdV-8 from gizzard erosions, however, the causal 
relationship could not be established [163, 199]. In 2017, it was shown in experimental 
studies that intranuclear inclusion bodies develop in the gizzard with infection with 
FAdV-1 but not with infection with FAdV-8a [200]. Today, the disease is widely 
prevalent in Japan [164, 201, 202], South Korea [203, 204] and European countries [165, 
205-208]. Besides broilers, gizzard erosion and ulcerations have also been documented in 
20 to 30 week old layer chickens [165, 200, 203]. More recently, they have been 
associated with increased mortality in pullets and decreased egg production in adult 
laying hens [200, 209]. The virus is epitheliotropic and multiplies in the epithelium of the 
proventriculus, gizzard and small intestines. However, the lesions mainly develop in the 
gizzard [165, 203]. Viral inclusions develop in infected epithelial cells in natural cases 
and experimental studies [198, 206]. Experimental infection of chickens with FAdV-1 by 
various routes reproduced clinical disease with characteristic lesions [165, 206, 208, 
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210]. Although the disease can be easily reproduced in embryos and day-old chicks 
following experimental infection, clinical manifestation at adult age requires additional 
unknown factors [209]. Loss of uniformity in broiler flocks and carcass condemnation are 
the most consistent findings. Since the chicken gizzard is a delicacy in Asian countries, 
condemnation of giblets (gizzards) is of considerable economic importance [189].  
 
1.9.6. Inclusion body hepatitis 
IBH mainly occurs in 1 to 5 week old broiler chickens. It has also been reported 
as early as 2 to 4 day old broiler chickens [211-213] and adult chickens (broiler breeders 
and layers) of varying ages [214]. The disease runs an acute course with sudden rise in 
flock mortality following a short incubation period (24 to 48 hours) which peaks at 3 to 4 
days post-infection gradually subsiding 5 to 6 days post-infection [215]. The mortality 
varies from as low as 1% [214] to as high as 30% [216-218], but often remains between 5 
to 10%. The variability in mortality mostly depends on factors such as the bird’s age, 
status of maternal antibodies, presence of immunosuppressive pathogens [18, 161, 189, 
219]. Swollen pale-yellow liver with widespread hemorrhages and necrosis in the 
parenchyma characterize the disease. Microscopically, hepatocyte necrosis and 
hemorrhage with basophilic intranuclear inclusion bodies are characteristic features of the 
disease. Inclusion bodies also develop in pancreas, small intestines and kidneys but are 
not consistent findings. Some early reports of disease from field outbreaks have also 
described eosinophilic inclusions, which usually lack virus particles. The disease is 
economically significant as there are huge monitory losses reported annually [220-222]. 
In the past, all serotypes (FAdV-1 to FAdV-12 of the old classification system of 
adenoviruses) were isolated from cases of IBH [3, 189, 216, 223-226]. It is highly likely 
as chickens are exposed to more than FAdVs [37, 227], but IBH has causal association 
with FAdV-2, FAdV-7, FAdV-8a, FAdV-8b and FAdV-11 [3, 214, 228, 229]. Recently 
Niczyporuk, (2016) reported occurrences of IBH due to FAdV-1 and FAdV-5 from 
Poland [212].  
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1.10. Pathobiology of IBH 
1.10.1. Epidemiology 
IBH was first described in 1963 by Helmboldt and Frazier as a disease of 
unknown significance in broiler chickens in USA [11]. Years later, Howell et al. (1970) 
first described necrotizing hepatitis with intranuclear inclusion bodies in hepatocytes in 
an outbreak of an unknown disease in broiler chickens in Ontario which killed 8% of the 
chickens in the flock [12]. Petits and Carlson (1972) reported another epidemic of a 
similar disease from broiler chickens in Ontario [13] and suspected a viral etiology. There 
were subsequent reports from Alberta [230] and Montreal [14] in 1974 with similar 
pathology. Today the disease has been reported from Australia [216, 229, 231, 232], New 
Zealand [217, 233-235], Asia [194], Middle East [236], Europe [237-239], Africa [240, 
241], North America [3, 161, 215, 219, 220, 242] and South America [243, 244], and an 
increased incidence has been reported from several countries in the past 10 years [236, 
240, 241, 245-249].  
Today, IBH is widely prevalent in various Canadian provinces and has become an 
economic concern [3, 161, 195, 215, 219, 250, 251]. Although the actual economic loses 
have not been assessed in the country, a report from Ontario estimated an annual figure of 
up to $300,000 in 2009 [222]. Several serotypes of FAdVs are present in Canada [3, 
195]. Ojkic et al. (2008) genotyped Canadian FAdV isolates isolated from Alberta, 
British Columbia, Saskatchewan, Manitoba, Ontario, Quebec, Nova Scotia [3]. These 
viruses have very close nucleotide identities to serotypes, FAdV-2 strains P7A and 
merlin, FAdV-7 strain x-11a like, FAdV-8a strains T8-A, TR-59 and Stanford, and 
FAdV-11 strain 1047. Some isolates originating from Saskatchewan also had 99.9% 
similarity to either FAdV-8a strain T8-A and FAdV-8b strain 764. The prevalence of 
FAdV serotypes varies due to spread of the virus. This was noticed heterologous FAdV 
serotypes broke the immunity induced by the  monovalent inactivated autogenous 
vaccine at affected farms [252]. The disease is remerging in western Canada as evident 
by fresh outbreaks of disease in Alberta and British Columbia recently. Thus, the disease 
is a lingering threat to broiler chicken production.  
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1.10.2. Pathogenesis 
Fowl adenovirus infection occurs in chickens by the fecal-oral, respiratory or by 
trans-ovarian routes [18, 189, 253]. FAdVs primarily replicate in respiratory tract 
epithelium or enteric epithelium (cecal tonsils) [189, 254, 255]. Following initial 
replication, viremia occurs and the virus spreads to other organs [256] including trachea, 
lungs, liver, pancreas, small intestine, cecal tonsils, renal tubular epithelium and bursal 
epithelium [184, 255-257]. Recently, Steer et al. (2015) studied the chronological 
development of the disease process in day old specific pathogen free (SPF) leghorn 
chickens by ocular route of infection using FAdV-1, FAdV-8b and FAdV-11 [231]. The 
disease development process is categorised into incubation (1-3 days post-infection), 
degeneration (4-7 days post-infection) and convalescent (12 days post-infection) stages 
based on hepatological lesion development [231]. Matos et al. (2016) have correlated 
abnormal biochemical parameters such as hypoglycemia and increased pancreatic lipase 
activity in sera of affected birds in acute phase of IBH when hepatic and pancreatic 
necrotic lesions predominat [257]. Virus infected cells are identified by the formation of 
basophilic intranuclear inclusion bodies, which are characteristic of viral replication [166, 
219, 231]. Upon completion of viral replication, the virus causes cellular lysis and leaves 
the body through respiratory or fecal excretions. If chickens are in egg production, the 
virus may transmit to eggs [189] and depending upon the immune status of the birds, may 
cause mortality in  progeny chicks. 
Pathogenicity of FAdVs varies with the strain or serotype of the virus, age, line 
and the immune status of the birds [81, 134, 214, 231, 257, 258] as well as the route of 
inoculation in experimental studies. So far, there is no concrete molecular evidence which 
differentiates FAdVs based on their virulence. Pallister et al. (1996) have differentiated 
pathogenic FAdV-8  strains from apathogenic strains by using fiber gene sequence [259]. 
However, it is not applicable to other FAdVs species [258]. The most reliable method to 
determine the pathogenicity of FAdVs is animal challenge and assessment of morbidity, 
mortality and severity of the lesions. Several researchers have used a SPF chicken model 
to study FAdV pathogenicity [43, 81, 134, 219, 239, 260]. Day-old SPF leghorn chicks 
are more susceptible to infection and their susceptibility decreases with age [219].  
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Disease development is also route dependent [219]. While clinical disease is 
reproducible experimentally in day-old chicks, intramuscular or intraperitoneal 
inoculation is necessary to reproduce disease in older birds [219]. In addition to routes of 
infection, differences in chicken lines (strains) affects the disease severity following 
FAdV infection. Matos et al. (2016) compared chicken-line susceptibility to pathogenic 
FAdV infection and reported that SPF broilers exhibited more severe disease, higher 
clinical and biochemical scores and higher mortality (100% vs 30-20%) then SPF leghorn 
chickens [257].  
 
1.10.2.1. Virulence factors of FAdV 
Virulence factors include structural and de-novo synthesized proteins which help 
the pathogens to infect cells, replicate within them, their release from infected cells and 
the infection of other cells as well as the mechanism of immune escape and 
immunomodulation [63]. Like other adenoviruses, FAdVs use fiber and penton proteins 
to infect the host cell [43]. FAdVs use the CAR receptor for preliminary interaction with 
the susceptible epithelial cells [261]. Since the CAR receptor is widely distributed in 
epithelial cells, FAdVs can infect the epithelial cells of respiratory, enteric, hepatic, and 
pancreatic as well as the epithelial lining of the bursa of Fabricius. Adenoviral penton 
protein is another protein which aids in viral infection. This protein is toxic and causes 
rounding of the cells. However, there is a lack of studies showing the same for FAdVs. 
Some de novo synthesized proteins such as GAM-1 and ORF-1 of FAdVs are capable of 
cellular transformation, though, this activity is limited to CELO virus only. Recently, 
Deng et al. (2013) have identified six ORFs (0, 1, 1A, 1B, 1C, and 2) on the left end of 
FAdV-9 that may be involved in immunomodulation and modulation of virus replication 
in chickens [80]. Besides this, there are also reports that FAdVs are capable of 
modulating cytokine responses that helps in virus persistence in the host [81, 82]. FAdVs 
augment the production IL-10, which suppress antiviral IFN-γ responses to FAdVs and 
may be an important factor in viral pathogenesis [81, 134].  
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1.10.3. Primary or secondary pathogens 
FAdVs are opportunistic pathogens but some of them can cause disease in the 
absence of immunosuppression and hence they are also known as primary pathogens of 
broiler chickens. FAdVs are frequently isolated from chickens that had suffered 
immunosuppression due to infectious agents such as IBDV [214, 226], chicken infectious 
anemia virus [214, 243, 262, 263] and less commonly with reovirus or parvoviruses [264, 
265]. Interestingly, this hypothesis is true as numerous researchers have reproduced 
FAdV diseases of greater severity following experimental immunosuppression by 
chemicals [226, 263, 266] or fungal mycotoxins [267]. These findings likely explain the 
field situation. 
Contrary to these studies, reports of IBH epidemics from Australia [216, 218, 
268] and New Zealand [217, 233, 269] in 1980 to 1990s and from Canada in 2006, 
documented no evidence of immunosuppression [161]. Experimental reproduction of 
these FAdV diseases by natural and experimental routes has confirmed the etiology of 
field outbreaks [219, 231] and hence, FAdV are considered primary pathogens of broiler 
chickens. Nevertheless, FAdVs can turn opportunistic in conjunction with 
immunosuppression and cause secondary disease [214]. 
 
1.10.4. Transmission  
1.10.4.1. Horizontal transmission 
Horizontal transmission is the most common mode of FAdV spread amongst 
chickens. Sub-clinically or clinically infected birds excrete FAdV in respiratory or fecal 
excretions and contaminate the environment. Susceptible birds become infected by the 
oral route [189]. Fecal shedding of FAdVs is species and age-dependent and is affected 
by immune status of the birds [270, 271]. Young birds shed FAdVs intermitantlyfor long 
periods of time, whereas adult birds shed low titer of virus in feces for a brief period 
[271]. Furthermore, peak shedding time is highly variable among FAdVs [270]. Fecal 
shedding is presumed to disappear with the development of virus-specific cellular and 
humoral immunity [271, 272]. The virus is spread among flocks by contaminated farm 
equipment, farm personnel and vehicles but rarely by aerosols [189]. Beside horizontal 
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transmission, FAdVs also maintain themselves in nature by way of vertical transmission 
from broiler breeder parents to their broiler progenies [18, 189]. 
 
1.10.4.2. Vertical transmission 
CELO virus was first discovered as an incidental finding in embryonated eggs in 
1957 [8] and later as a contaminant of vaccines originating from chicken eggs [9]. 
Subsequently, wide-spread seropositivity was reported in chickens to CELO virus in 
Japan and USA [8, 10] and therefore, for the first time, egg transmission was suspected  
To understand egg transmission of CELO virus and other FAdVs, various researchers 
have conducted experimental studies or field investigations of FAdV infections to 
unravel the evidence [223, 243, 251, 254, 272-274]. Vertical transmission has been 
reported experimentally for FAdV-1 [206, 272, 273] and FAdV-4 [223, 243], which 
causes gizzard erosions and ulcerations and HHS in broiler chickens, respectively. It is 
speculated that FAdV may establish latent infections in chicken tissues similar to HAdVs 
[251] and become reactivated at the time of sexual maturity [275]. Although, 
experimental evidence is not available on vertical transmission of FAdVs which cause 
IBH, some field surveys have demonstrated viral antigens of FAdV-8 in egg contents  
[254] or viral DNA in tissues [251]. Infectious virus was not demonstrated in these 
studies. Time of occurrence of vertical transmission is another area that needs 
investigation. Cowen et al. (1978) and Dawson et al. (1981) have reported the occurrence 
of vertical transmission of FAdV-1 and CELO virus seven days post-infection [273, 275]. 
It is uncertain or undetermined for other serotypes. In addition to the period of 
transmission, researchers have also correlated vertical transmission to the development of 
virus-specific antibodies. While one faction of investigators has reported cessation of 
vertical transmission following seroconversion of experimentally infected chickens [272, 
273, 275], others disagreed [223, 254]. Nevertheless, vertical transmission is always 
suspected upon isolation of a heterologous virus from broiler chickens that originate from 
vaccinated flocks [229] or if a shift in the occurrence of the disease to a younger age 
compared to its usual occurrence at 2 to 5 weeks of age [213, 220]. 
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1.10.5. Diagnosis  
Traditionally, the clinical history of the disease, gross and microscopic lesions or 
electron microscopic examination of infected tissues were the methods to establish a 
diagnosis of FAdV infections. FAdVs can be identified by various methods such virus 
isolation in embryonating eggs, primary cell culture and continuous cell lines. Viruses 
can be detected by identifying virus nucleic acids or viral antigens in tissues or by 
measuring virus-specific antibodies in the serum sample. Among these, serological tests 
and molecular diagnostic methods are the preferred tests in diagnostic or experimental 
laboratories around the world.  
 
1.10.5.1. Virus isolation 
FAdVs grow in embryonating eggs via inoculation of the chorioallantoic and 
yolk-sac routes [18, 276], or in primary cell cultures derived from chicken embryo 
fibroblast [277], chicken embryo kidney cells and chicken embryo liver cells [43, 206, 
223, 260]. In addition to primary cell cultures, many researchers have used continuous 
cell lines of chicken origin to propagate FAdVs. These are chicken hepatoma cell line 
(CH-SAH) [134, 221, 278] and leghorn male hepatocellular carcinoma cell line (LMH) 
[279]. FAdV infection cause rounding and detachment of cells, which appear refractile 
under a light microscope (Figure 1-6). 
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Figure 1-6: Normal and FAdV infected cells. (A) Normal stellate LMH cells. (B) 
FAdV infected cells. The infected cells were round, detached from surface and refractile 
in nature.  
 
1.10.5.2. Serological tests 
Serological tests are invaluable tools to confirm infection status in the absence of 
tissue samples. Serological tests can be as simple as agar gel immunoprecipitation 
(AGID) to more sophisticated tests such as enzyme-linked immunosorbent assays 
(ELISA). Serological tests monitor antibody response due to routine vaccination or 
infection. These tests are the critical components of epidemiological studies to determine 
the prevalence FAdV infections in flocks. Several studies have documented the use of 
serological procedures such as AGID to determine the FAdV status of the chickens [18, 
191, 280]. However, the poor detection limit of AGID sometimes give false negative 
results [18]. In addition to AGID, many researchers have used ELISA to rule out the 
FAdV status of flocks or to determine antibody responses to FAdV infection in 
experimental studies [18, 215, 281]. AGID and ELISA detect antibody responses, these 
tests fail to differentiate among serotypes of FAdVs due to masking effects of group-
specific antibodies [18, 281, 282]. Recently, it has been shown that antibodies developed 
against the FAdV fiber (FAdV-1, -2, -4, -8a, -8b and -11) can be exploited to distinguish 
between these FAdVs using ELISA [283, 284]. Interestingly, the results have shown 
some correlation with neutralizing antibodies. Virus neutralization tests (VNT) detect 
A
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virus-specific anti-FAdV fiber antibodies. This technique differentiates FAdV into 
serotypes [189]. This test is the principle method to establish a serotype specific 
diagnosis. Virus-specific antibodies have also been used to determine virus replication 
sites in tissues by using immunohistochemical methods [256].  
 
1.10.5.3. Molecular tests 
PCR has revolutionized FAdV diagnostics. PCR alone or in combination with 
restriction enzyme analysis has been used to differentiate FAdVs into different genotypes 
[36, 37, 285-287] based on their electrophoretic mobility in agarose gel. RFLP techniques 
gained popularity following the pioneering work of Zsak and Kisary (1984) [35], who 
first used this method to differentiate avian adenoviruses. PCR along with DNA 
sequencing of the hexon gene more accurately differentiate FAdVs into different 
genotypes and are extensively used to establish evolutionary relationships with newly 
identified FAdVs [3, 204, 214, 288-290]. In addition to FAdV hexon gene sequencing, 
Schachner et al. (2016) have also used fiber-gene sequence to differentiate FAdV 
serotypes [291]. In the last decade, researchers have devised faster ways to genotype 
FAdVs within hours with high accuracy and confidence by using high resolution melt 
curve (HRM) analysis of the hexon gene in a real-time (rt)-PCR platform [229, 292, 293]. 
Although, experimental data indicated a considerable consensus between genotyping and 
serotypes based on HRM analysis of the hexon gene [229], sometimes more than one 
technique is  required to establish the identity of the virus. 
 
1.11. Control of IBH 
Strict biosecurity and farm hygiene are of prime importance.  Any breach of these 
invites infectious diseases to the chicken barns. Besides biosecurity at an acceptable 
level, sound vaccination programs aid in the prevention of IBH.  
Chickens contract FAdV infections by either horizontal or vertical transmission 
[189]. While strict biosecurity can control the horizontal spread of the virus, it is 
impossible to prevent vertical transmission of FAdVs without vaccinating broiler 
breeders. Therefore, vertical transmission control strategies are mainly focused on 
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vaccinating broiler breeders to induce antibodies against FAdVs [189]. Seroconversion of 
breeders before egg-laying aids in the prevention of vertical transmission [272, 273]. 
Moreover, it allows maternal antibody transfer to progenies, which protects them from 
FAdV exposure in neonatal life [294]. Exposure of hens to heterologous viruses breaks 
the maternal antibody barrier and causes disease in broiler progenies [229, 295]. 
Therefore, the effective preventative strategy requires vaccines that confer broad-
spectrum protection against various FAdVs. In addition to FAdV vaccination, vaccination 
for immunosuppressive agents is also recommended as an aid to prevent opportunistic 
infections by FAdVs [243, 295]. Li et al. (2017) comprehensively reviewed various 
approaches of vaccinology for FAdV disease control. These include live vaccines, 
autogenous inactivated vaccines, inactivated vaccines of cell culture and egg origin virus 
as well as subunit vaccines [296].  
 
1.11.1. Live vaccines 
Live virus vaccines are economic, efficacious and easy to administer for mass 
vaccination. Numerous live vaccines are in use to control infectious viral diseases of 
poultry such as NDV, infectious laryngotracheitis and infectious bronchitis [297-299]. At 
present, a monovalent live FAdV (FAdV-8b) vaccine is approved for broiler breeder 
vaccination programs in Australia to protect broilers from IBH caused by FAdV-8b [229, 
232]. The vaccination strategy includes oral exposure of increasing percentage of birds 
multiple times between 6 and 30 weeks of age until they develop sufficient antibody 
levels. Besides IBH, live FAdV vaccines have been developed against HHS (FAdV-4) by 
attenuating live FAdV-4 strains in embryonated chicken eggs and QT cell lines [260, 
300]. Protection up to 97.7 to 100% has been demonstrated in vaccinated chicks 
following lethal virus exposure in these studies [260, 300]. Despite their advantage, an 
important implication of live virus vaccines is fecal shedding by vaccinated birds until 
immunity develops. Chicks shed FAdVs intermittently for several days [253, 270, 271].  
Therefore, it is important to characterize FAdV infections in broiler breeders to determine 
the duration of virus shedding, to study immunity and to assess the role of immunity in 
prevention of viral shedding.  
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1.11.2. Inactivated vaccines 
Most countries rely on inactivated autogenous liver tissue, cell culture or egg 
propagated inactivated vaccines to vaccinate broiler breeders [161, 162, 186, 192, 294, 
301]. The inactivated vaccines are formulated with mineral-oil or aluminium hydroxide 
adjuvants and are administered by intramuscular injection into pectoral muscles in 
breeders. FAdV vaccines are also formulated as inactivated polyvalent vaccines along 
with other avian viruses such as NDV and egg drop syndrome in some countries [302]. 
The protection rate varied from 80 to 100% with inactivated FAdV-4 in against HHS 
[303], 90- 100 % against IBH (FAdV-2) [304] and 98 % against FAdV-8, 92% against 
FAdV-11 [294]. 
 
1.11.3. Subunit vaccines 
Besides live and inactivated vaccines, several researchers have also developed 
and tested subunit vaccines for the prevention of FAdV diseases [43, 305-308] mainly 
HHS and non-FAdV adenoviral disease of chickens (egg drop syndrome) and turkeys 
(hemorrhagic enteritis) [181, 309]. Shah et al. (2012) reported 90% protection against 
HHS in broilers vaccinated with FAdV-4 penton subunit vaccine [306]. Approximately 
62% and 96% protection has been reported in SPF chickens against HHS vaccinated with 
fiber-1 and fiber-2 FAdV-4 subunit vaccines [43]. More studies that are recent have 
shown 90-100% protection against HHS in SPF chicks that were vaccinated with fiber-2 
subunit vaccine of FAdV4 [307, 308]. The protection was modest (22% and 40%) with 
subunit hexon, penton, fiber-1 and 100k vaccine against HHS [305, 306]. However, it 
was improved by increasing the dose of subunit vaccine (hexon and fiber-1) against HHS 
[308] .Similar developments are lacking for IBH causing FAdVs. 
 
1.11.3.1. Adjuvants 
Adjuvant discovery is an active area of research and development for better 
delivery of inactivated or subunit vaccines. Adjuvants are essential component of 
inactivated vaccines and are required for inducing a superior immune response. 
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Emulsions of oil and water in various combinations such as water-in-oil (W/O), oil-in-
water (O/W), water-in-oil-in-water (W/O/W) are primarily used in poultry vaccines. The 
use of saponins and alum-based adjuvants has also been reported [310, 311]. Among 
these, W/O adjuvants are most robust, efficacious and safe formulations [312]. W/O 
comprises tiny water droplets dispersed in oil. The preparation acts like a depot injection 
in tissues, which slowly releases the antigen to induce a sustainable immune response by 
inducing inflammatory responses aiding in antigen uptake and subsequent stimulation of 
the immune system. Researchers are testing new formulations of W/O adjuvants in 
poultry vaccines to minimize tissue reaction associated with them. Contrary to W/O 
adjuvants, O/W adjuvants have oil phase dispersed in water allowing them to quickly 
release the antigens, inducing strong but brief immune response. Oils of animal, 
vegetable or synthetic origins are commonly used in these preparation and are shown to 
be effective in poultry vaccines [313].  
The aim of inactivated and subunit vaccines is to induce high-levels of antibodies 
in hens before egg laying to ensure maternal antibody transfer to progenies. Therefore, 
adjuvants that skew immune responses to Th2-type immunity are highly desired in 
poultry vaccines. Several W/O emulsion adjuvants of Montanide series (Seppic, France) 
and O/W mineral oil emulsions (Emulsigen-D) (MPV Technologies Inc.) were studied in 
experimental avian viral or bacterial vaccines. They mainly favor T helper (Th)-2 type 
immune responses [314, 315]  similar to alum adjuvants. Besides chemical adjuvants, 
microbial components, such as interleukins (e.g. IL-18), interferons (e.g. IFN-γ), avian-b 
defensins, pattern recognition receptors such as CVCVA5 (combination of polyriboinosic 
polyribocytidylic, resiquimod, muramyl dipeptide and levamisole) and non-methylated 
prokaryotic DNA [221, 316-320]. Synthetic CpG-ODN is an analog of microbial DNA 
that has been extensively studied for its immune stimulatory properties [314, 318, 321, 
322], as a vaccine adjuvant or as an in ovo immunostimulant [321, 323]. There are 
various type of CpG-ODNs [324] differing in their backbone and physicochemical 
properties. They stimulate different immune cells, act by different subcellular pathways 
and induce different cytokines [324]. CpG-ODN is sensed as a foreign molecule by 
mammalian cells as it lacks methylation at cytosine residues and triggers cytokines and 
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chemokine responses upon recognition of TLR-9 (or chTLR-21 in chickens) [321]. CpG-
ODN is a potential vaccine adjuvant in poultry vaccines in the future as it adjuvants with 
minimal or no tissue reaction [318] and potential low cost to benefit ratio [322]. Previous 
studies have analyzed its adjuvanticity for short-term studies of 6 to 7 weeks. Whether it 
can induce and maintain antibody levels similar to W/O emulsions needs investigation.  
 
1.12. Current problems associated with IBH in Canada 
IBH is the only FAdV disease present in Canada. FAdVs of species E (FAdV-8a, 
-8b and -7) and D (FAdV-11 and FAdV-2) are the most prevalent viruses in Canada. At 
present, commercial FAdV vaccines are not marketed in Canada. Broiler breeders are 
vaccinated with autogenous inactivated vaccines in endemic areas as a preventative 
measure against IBH. Despite their use, sporadic outbreaks of IBH commonly occur as a 
result of heterologous FAdVs, which are not controlled by the autogenous vaccine. 
Moreover, autogenous vaccines lack potency and efficacy data. Multivalent FAdV 
vaccines, which are safe and efficacious, and offer broad-spectrum protection against 
multiple serotypes are needed. Also, for industry feasibility and commercialization 
purpose, methods of mass production and mass application need to be considered. 
Therefore, the objective of this project was to develop a live FAdV vaccine using wild-
type FAdVs and compare its efficacy with an inactivated FAdV vaccine. In addition to 
conventional vaccines, the possibility of a subunit vaccine and suitable adjuvants for 
inactivated vaccines were explored. Briefly, the goals of this project are divided into 
three objectives as follows:  
 
1.13. Objectives 
1. Control of IBH in the Canadian broiler chicken industry with a live or inactivated 
FAdV vaccine. 
2. Selection of appropriate adjuvant(s) for an inactivated FAdV vaccine. 
3. Control of IBH in Canada using a FAdV subunit vaccine. 
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2.1. Abstract 
FAdV is comprised of five species (A to E) and 12 serotypes (1-7, 8a, 8b, 9-11).  
IBH is caused by FAdV-7, -8a, -8b (species E) and FAdV-2 and FAdV-11 (species D). 
Commercial vaccines against IBH are not available in Canada. Autogenous FAdV broiler 
breeder vaccines are now used in some areas where outbreaks of IBH are occurring. The 
objective of this study was to evaluate the efficacy of a bivalent (species D and E) live 
and an inactivated FAdV broiler breeder vaccine in protecting broiler chicks against IBH 
through maternal antibody (MtAb) transfer. FAdV seronegative broiler breeders 
(n=300/group) received either a live or inactivated bivalent (FAdV-8b-SK+FAdV-11-
1047) vaccine. The live vaccine (1x104 TCID50 of each virus/bird) was given orally once 
at 16 weeks of age and the inactivated vaccine (1x106 TCID50 of each virus+20% 
Emulsigen-D) was given intramuscularly at 16 and 19 weeks of age. Controls (n=150) 
were given saline orally. The inactivated vaccine group was boosted 3 weeks later with 
the same vaccine. Neutralizing antibodies (NAb) in sera (n=10) were detected at 19, 22, 
30 and 48 weeks of age. NAb were able to neutralize various FAdV serotypes within 
species D and E. Mean NAb were similar in the both live and killed vaccine groups at 19, 
30 and 48 weeks and ranged from 2.40 log10 to 3.70 log10. Approximately 26±7% of 
MtAbs were passively transferred through eggs to day-old chicks. Progeny challenged 
with a lethal dose (1x107 TCID50/bird intramuscularly) of FAdV-8b-SK, FAdV-11-1047, 
or FAdV-2-685 (n=90/group) at 14 days post-hatch (dph) showed 98-100% protection in 
broiler chicks to homologous or heterologous FAdV challenges. Our data suggests that a 
bivalent live and an inactivated FAdV vaccine are equally effective and have the 
potential for the control of IBH. 
 
2.2. Introduction  
IBH is an economically important FAdV disease of 2 to 5 week old broiler 
chickens [189, 231, 279]. The disease has also been reported within a week of hatch in 
broilers [213] as well as in pullets [214]. IBH is characterized by increased flock 
mortality that varies between 2% to 30% [214, 216, 219]. Although five species (A to E) 
and 12 serotypes (1-7, 8a, 8b, 9 to 11) of FAdVs are known [270, 279], IBH is primarily 
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caused by FAdV-7, -8a and -8b of species E and FAdV-2 and FAdV-11 of species D [3, 
161, 214, 215, 229]. FAdV-8a, -8b and -11 are the predominant serotypes associated with 
outbreaks of IBH in Canada [3, 195]. The existence of multiple FAdV serotypes and 
species and lack of interspecies protection makes controlling IBH difficult [189]. Hence, 
a broad-spectrum FAdV vaccine is needed for the prevention of IBH. 
Since licensed FAdV vaccines are not available in Canada [3, 221], broiler 
breeders in areas with significant IBH losses are vaccinated with autogenous vaccines for 
the prevention of disease in their progeny. Several researchers have evaluated inactivated 
FAdV vaccines of liver-tissue, cell-culture or egg origin in broilers against HHS [192, 
193, 301, 325-327] or in broiler breeders against IBH [294, 304]. HHS is an acute FAdV 
(FAdV-4) disease of 3 to 6 week old broiler chickens, which can cause 30-70% mortality 
in susceptible flocks. Inclusion body hepatitis, hydropericardium, pulmonary hemorrhage 
and nephrosis are characteristic lesions of the disease [300, 301]. Inactivated FAdV 
(FAdV-4) vaccines have been used in various viral doses (1x103.8 EID50 [326], 5x10
5.5 
TCID50 [301, 325] or 1x10
6 TCID50 [193]) for providing immunity in chicks against HHS 
between 7 to 42 days post-vaccination (dpv). An inactivated FAdV (FAdV-2) vaccine 
(1x106 TCID50)  was shown to protect chicks against IBH by MtAb transfer from 
vaccinated breeders [304]. Like inactivated vaccines, live FAdV vaccines protect 
chickens against FAdV diseases [260, 300]. Live attenuated FAdV-4 vaccines have 
shown protection against HHS when used at a dose of 1x103.3 EID50 [300] or 5x10
4 
TCID50 [260] in day-old chicks. Apart from attenuated FAdVs, wild-type FAdV (FAdV-
8b) virus (1x103 TCID50 per bird) has been used as a broiler breeder vaccine by protecting 
broiler chicks through MtAb [229].   
These studies have led to monovalent FAdV vaccines based on FAdV-4 which 
can help in preventing HHS, but not necessarily IBH, as the latter is caused by multiple 
serotypes [189] Monovalent vaccines do not cross-protect against heterologous FAdV 
species [189, 229]. For the effective prevention of IBH, multivalent vaccines are needed. 
Multivalent vaccines have been shown to provide broad-spectrum protection against 
avian viruses [294, 328, 329]. Therefore, the goal of this study was to compare and 
evaluate the efficacy of a bivalent (FAdV-8b+FAdV-11) live versus a bivalent (FAdV-
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8b+FAdV-11) inactivated broiler breeder vaccine for the protection of broiler chicks 
against IBH by MtAb transfer. 
 
2.3. Materials and methods 
2.3.1. Propagation of FAdVs for FAdV vaccine 
Plaque purified FAdV-8b-SK [279] and FAdV-11-1047 (Animal Health Lab, 
University of Guelph, Ontario) were propagated in LMH cells by infecting 80% 
confluent cells at a multiplicity-of-infection of 5. The cells were incubated for 1 h at 37 C 
and 5% CO2 and subsequently replenished with Dulbecco’s Modified Eagle Medium: 
Nutrient Mixture F-12 (DMEM: F-12) (Thermo Fisher Scientific) supplemented with 5% 
fetal bovine serum, 20 mM glutamine, 2 mM HEPES and 1:1000 gentamicin (100 µL of 
50 µg/mL per 100 mL of media). The infected cells were harvested 72 h post-infection 
(FAdV-8b-SK) or 96 h post-infection (FAdV-11-1047), freeze-thawed five-times and 
centrifuged at 3000 rpm to separate the supernatant. The supernatant was tittered by Reed 
and Muench method [330]. 
The live bivalent FAdV vaccine was prepared by mixing FAdV-8b-SK and 
FAdV-11-1047 in sterile saline to obtain a dose of 1x104 TCID50 of each serotype.  
Similarly, the inactivated bivalent FAdV vaccine (heat inactivation at 64 C for 1 h) was 
prepared by mixing FAdV-8b-SK and FAdV-11-1047 with 20% Emulsigen-D (MVP 
Laboratories, Omaha, NE) and sterile saline to make a dose of 1x106 TCID50 of each 
serotype. The final volume of the vaccine dose was 0.5 mL per bird.  
 
2.3.2. Preparation of FAdV inoculum for broiler challenge  
FAdV-8b-SK or FAdV-11-1047 infected livers of SPF broilers were macerated in 
a mortar by a pestle and Waymouth’s media (Thermo Fisher Scientific) was added to 
make a 40% liver homogenate. The homogenate was freeze-thawed (5X) to release the 
virus into the supernatant, which was later separated by centrifugation at 6000 rpm for 30 
min at 10 C. The supernatant was filter sterilized using 0.22 m syringe-filters (Cameo, 
Maine Manufacturing LLC) and titrated as described above. FAdV-8b-SK and FAdV-11-
1047 hexon genes were amplified with in a standard polymerase chain reaction using Hex 
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A/B primers [37] and the identity was confirmed by analyzing 158 amino acid long 
sequence between position 130 to 287 as described previously [3]. 
 
2.3.3. Safety evaluation of live FAdV in broiler breeders 
The safety of the wild-type live FAdV was evaluated in broiler breeders by 
intramuscular vaccination (n=20 females+4 males) with FAdV-8b-SK (1x107 TCID50 per 
bird) at 29 weeks of age. Eggs, sera and blood (n=5) were collected for 1 week before 
vaccination (control). Following vaccination, fecal samples (n=6) were collected at 1, 3, 
7, 10, 14, 17 and 21 dpv to determine fecal shedding. Blood samples (n=5) were collected 
at 2, 3, 7, 10, 14, 17 and 21 dpv to detect viremia and 7, 14 and 21 dpv to measure NAb. 
Eggs were collected in weekly batches for 3 weeks to detect egg transmission of FAdV-
8b-SK. The experiment was terminated at 21 dpv and liver, spleen, kidney, ovarian 
follicles and cecal tonsils (n=5 females and 1 male) were collected for virus isolation and 
DNA detection. We also examined the safety of the live bivalent FAdV-8b-SK+FAdV-
11-1047 vaccine. Broiler breeders were orally administered 1x104 TCID50 of each 
virus/bird once at 16 weeks of age.  Eggs were collected 9 weeks after the breeder 
vaccination from both the vaccinated and saline control groups.  Mortality was recorded 
in the progeny from both groups. Post-mortem examinations were conducted on dead 
birds and virus detection was done using cell culture and PCR techniques. 
 
2.3.4. Animals and experimental design 
Day-old (Ross) broiler breeders were obtained from Aviagen Inc. (Huntsville, 
AL) and were reared in the Animal Care Unit, Western College of Veterinary Medicine, 
University of Saskatchewan as per Aviagen guidelines. Their FAdV seronegative status 
was confirmed by a virus neutralization test (VNT) at 15 weeks of age. Broiler breeders 
were randomly allocated into three groups: live (n=300), inactivated (n=300), and control 
(n=150). The live vaccine group was vaccinated once orally with the live bivalent FAdV 
vaccine (1x104 TCID50/ bird) at 16 weeks of age. The inactivated vaccine group was 
vaccinated intramuscularly with the inactivated bivalent FAdV vaccine (1x106 
TCID50+20% Emulsigen-D/bird) at 16 and 19 weeks of age. The control group received 
  
 43 
 
 
saline orally at 16 and 19 weeks of age.  Following vaccination, NAb were determined in 
sera from all groups (n=10) at 19, 22, 30, and 48 weeks of age. Fecal shedding was 
determined by detecting virus in cell culture and quantifying viral DNA in cloacal swabs 
(n=10) from the live vaccine and control groups at 7, 14, 21 and 35 dpv.  
 Eggs were collected from broiler breeders at 30 weeks of age to hatch the broilers 
for challenge protection studies.  Day 0 sera samples (n=10) were collected  to determine 
the percentage of MtAb transfer [102]. MtAb mediated protection was assessed by 
challenging randomly selected broiler chicks (n=90/group) intramuscularly with 1x107 
TCID50 of FAdV-8b-SK, FAdV-11-1047 or FAdV-2-685 liver homogenates at 14 dph. 
The broilers were monitored for 10 days post-challenge for clinical signs and mortality. 
Liver samples from dead or euthanized birds were preserved in 10% formalin to confirm 
IBH by histopathology. 
 
2.3.5. Measurement of neutralizing antibodies against FAdVs 
NAb against FAdV-2-685, FAdV-7-x-11a like, FAdV-8b-SK, FAdV-8a-TR59 
and FAdV-11-1047 were measured by VNT [279]. Two-fold serially diluted heat 
inactivated (56 C, 30 min) sera were mixed with 200 TCID50 of FAdV. Samples were 
incubated at 37 C and 5% CO2 for 1 h and then transferred to 96 well plates seeded with 
5x104 LMH cells. Cytopathic effects were investigated day 7 post-incubation. 
 
2.3.6. Quantitation of fecal shedding in cloacal swabs 
Cloacal swabs (n=10) were collected in Luria broth and used to inoculate LMH 
cells to determine virus titer [279]. The shedding pattern was determined by measuring 
FAdV-DNA copy numbers using the standard curve method in rt qPCR [270]. FAdV-
DNA was amplified in a 25 µL reaction from 200 ng of total DNA (Qiagen Viral RNA 
mini kit) using FAdV-species-E/D primer-probes (Table 2-1) in 2-step fast cycle program 
(MxPro-3005P, Agilent Technologies). Following the initial denaturation at 95 C for 10 
min, 40 cycles of denaturation at 95 C for 15 sec, and extension at 60 C for 45 sec were 
used for DNA amplification.  
  
 
   
  
 
4
4
 
 
Table 2-1: Primer-probe sequences used for real-time qPCR 
 
Primer ID 5’-3’ Sequence  Position 
FAdV-08_For_122001 5'-TAC CCG CAA TGT CAC TAC CGA GAA-3'  20701-20724 
FAdV-08_Rev_122001 5'-CCT TTG ATG TCG AAG TAG GTC GCT-3'  20859-20836 
FAdV-08_Rev_122001 5’-6-FAM-CCCAGCGGCTTCAGATCAGGTTCTA-TAMARA-3’ 20727-20751 
FAdV-2/11_For_122001 5'-GCT CAG AGG CTT CAG ATC AGG TTT-3'  20159-20182 
FAdV-2/11_Rev_122001 5'-AAC CCA ACT GTC GCC CAC GTT TA-3'  20257-20235 
FAdV-2/11_Pr_122001 5’-6-FAM-AACAGTTACCGCGTGCGGTACAGTT-TAMARA-3’ 20210-20234 
The primer-probe positions are based on the reference virus FAdV-8 isolate HG, (gene bank reference # = GU734104) and FAdV-2 (gene bank 
reference # = AC_000013).  
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2.3.7. Statistical analysis  
Differences in mean NAb titers of breeders was tested using the Student t–test 
with Welch’s correction for the unequal variance (PRISM, Graph Pad, Inc. San Diego, 
CA). Survival analysis of the challenge protection experiments was performed by the 
Mantel-cox (Log-rank) test. The results were considered significant at P<0.05. 
 
2.4. Results 
2.4.1. Safety of live FAdV virus in broiler breeder 
 We first investigated the safety of the live wild-type FAdV-8b-SK virus as a 
broiler breeder vaccine. Broiler breeders vaccinated with the wild-type FAdV-8b-SK did 
not exhibit clinical signs, but were viremic at 2 and 3 dpv (16.6%) and were shedding 
FAdV-8b-SK in feces from 1 dpv through 14 dpv (Figure 1A). NAb developed as early 
as 7 dpv which increased to a higher level at 14 and 21 dpv (Figure 1B). No pathological 
lesions were present in the organs at 21 dpv but a few samples of the kidney (1/6), 
pancreas (2/6), cecal-tonsils (4/6), ovarian follicles (2/6), and shell glands (2/6) were 
positive for FAdV DNA in qPCR. We next examined the duration of a possible viral 
transfer to progeny through eggs and eventually pathogenicity in chicks. Very high 
mortality (72.2%) due to IBH was observed in the progeny hatched from the eggs 
collected during the first-week post vaccination (Figure 1C). However, progeny chicks 
hatched from the eggs collected during the 2nd and 3rd weeks after vaccination had 
MtAb (Figure 1D) and were free of clinical disease.  
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Figure 2-1: Safety evaluation of wild-type live FAdV-8b-SK in broiler breeders in 
egg production (29 weeks of age). (A) Fecal shedding by the broiler breeders post-
vaccination. The limit of detection of rt qPCR was 36 copies (~ CT number 35.98). 
Samples used for our analysis had CT numbers ≤ 35. (B) NAb response post-vaccination. 
(C) Mortality in 1st, 2nd and 3rd week broiler chicken progeny. (D) Kaplan Meier survival 
estimates. Maternal NAb titers in broiler chicken progeny, P<0.05. 
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We also vaccinated broiler breeders orally once at 16 weeks of age with a live 
bivalent FAdV-8b-SK+FAdV-11-1047 vaccine (1x104 TCID50 of each virus/bird) to 
examine the possibility of transmission of the vaccine virus to progeny more than 9 
weeks after the breeder vaccination. We did not find any vaccine virus transmission to 
the progeny. The percent mortality in chicks hatched from the live vaccinated and saline 
groups for 2 weeks post-hatch (n=90) were 1.1% and 2.2%, respectively (Figure 2-2). 
The causes of death were sudden death syndrome and ascites. Samples collected from the 
dead birds did not show evidence of vaccine virus in either cell culture or PCR detection, 
suggesting a NAb response in broiler breeders. 
 
Figure 2-2: Breeder vaccination with live bivalent FAdV-8b-SK+FAdV-11-1047 
vaccine at 16 weeks of age is safe and does not cause mortality in hatching chicks 
and vertical transmission of the vaccine viruses. Percent mortality in the chicks that 
were hatched from live vaccinated group and saline group for 2 weeks post- hatch 
(n=90). The mortality percentage was 2.2% in chicks hatched from saline control 
breeders and 1.11% in chicks hatched from live vaccinated breeders, respectively. The 
cause of death was sudden death syndrome and ascites. No IBH specific lesions were 
present. FAdV was not detected by PCR and cell culture in chicks 
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2.4.2. Neutralizing antibody response in broiler breeders 
Control broiler breeders remained seronegative throughout the experiment. NAb 
were detected against FAdVs in groups vaccinated either with either the bivalent live or 
inactivated FAdV vaccine. The mean NAb titer against the FAdV-8b-SK bivalent live or 
inactivated FAdV vaccine group at 19 weeks of age were 2.80 log10±0.45 and 3.10 
log10±0.37 respectively (Figure 2-3A). NAb titer against FAdV-8b-SK reached the 
highest level at 48 weeks of age in both the live and inactivated vaccine groups. NAbs 
against FAdV-11-1047 were also detected and were maintained between 3.20 log10±0.37 
and 3.60 log10±0.31 in both vaccine groups from 19 through 48 weeks of age (Figure 
2-3B). 
 
Figure 2-3: NAb response of broiler breeders.  NAb response of broiler breeders to 
live and inactivated bivalent FAdV vaccines at various time points post-vaccination, 
Mean±SD, n=10. (A) FAdV-8b-SK (B) FAdV-11-1047. The control broiler breeders 
were serologically negative throughout the experiment.  
 
 
 
 
 
 
A B FAdV-8b-SK FAdV-11-1047 
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2.4.3. Cross-neutralizing antibody response against heterologous FAdVs  
Cross-NAb were determined against heterologous FAdV-2-685 FAdV-7-x11a and 
FAdV-8a-TR59 in live (Figure 2-4A) and inactivated vaccinated (Figure 2-4B) broiler 
breeders at 19, 22 and 48 weeks of age. The NAb varied between 3.0 log10±0.40 to 3.70 
log10±0.40 in the live vaccinated breeders and between 2.40 log10±0.17 to 3.70 log10±0.20 
in the inactivated vaccinated breeders during 19 to 48 weeks of age. 
 
Figure 2-4: Comparison of cross-neutralizing antibody levels with heterologous 
FAdV serotypes. Cross-neutralizing antibodies (NAb) against FAdV-7-x-11a like, 
FAdV-8a-TR59 (species E) and FAdV-2-685 (species D) in live and inactivated bivalent 
(FAdV-8b-SK+FAdV-11-1047) FAdV vaccine groups at 19, 22 and 48 weeks of age, 
Mean±SD, n=10 birds. Control breeders were serological negative throughout the 
experiment. 
 
2.4.4. Fecal shedding of FAdVs in broiler breeders vaccinated with live 
bivalent FAdV vaccine 
FAdV shedding was not detected in the control breeders. However, FAdV 
shedding in feces was detected in broiler breeders vaccinated with a live vaccine (FAdV-
8b-SK+FAdV-11-1047). Infectious virus was detected in the feces of 90% of broiler 
A B Live bivalent vaccine Inactivated bivalent vaccine 
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breeders (9/10) at 7 dpv. The number of infectious shedders declined to 10% (1/10) at 14 
dpv and no virus was detected thereafter. The mean FAdV titer (TCID50/mL) at 7 and 14 
dpv was 3.60 log10 and 3.40 log10 respectively. Figure 2-5 shows virus specific fecal 
shedding by live vaccinated breeders. FAdV-8b-SK DNA was detected in 90% (9/10) 
and 70% (7/10) birds at 7 and 14 dpv, respectively and 10% (1/10) of the birds at 21 dpv. 
Likewise, FAdV-11-1047 DNA was detected in 100% (10/10) of the birds at 7 dpv, 30% 
(3/10) of the birds at 14dpv and 10% of the birds at 21 dpv. No viral DNA was detected 
for either virus at 35 dpv.  
 
  
Figure 2-5: Fecal shedding of FAdVs in broiler breeders vaccinated with live 
bivalent FAdV vaccine. FAdV DNA copy number in cloacal swabs of broiler breeders 
vaccinated with live bivalent (FAdV-8b-SK+FAdV-11-1047) vaccine at various time 
points post vaccination, Mean±SD, (n=10). Limit of detection of rt qPCR was 36 copies 
(~ CT number 35.98). Samples used for our analysis had CT numbers ≤ 35.  
 
2.4.5. Maternal antibodies and protection of broilers against FAdV challenge  
MtAb levels were measured in day-old chick sera by VNT. Figure 2-6A 
demonstrates the MtAb level against FAdV-8b-SK in the live and inactivated vaccine 
groups. These were 2.90 log10±2.70 in and 2.90 log10±0.0, respectively. Figure 2-6B 
shows the MtAb titer against FAdV-11-1047 in the live and inactivated vaccine groups 
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which were 2.60 log10±2.60 and 2.20 log10±1.90 respectively. MtAb levels in day-old 
chicks constituted 26.6±7.40% [32.2±0.04% (live vaccine) and 21±0.04% (inactivated 
vaccine)] of NAb levels of broiler breeders at 30 week of age. 
 
Figure 2-6: Maternal NAb levels in day old broiler chicken progeny.  Mean MtAb 
(n=10) in the progeny of live and inactivated vaccinated broiler breeders at day 0, 
Mean±SD, (n=10). (A) FAdV-8b-SK. (B) FAdV-11-1047.  
 
The protective efficacy of MtAbs were evaluated by exposing broiler progenies to a 
lethal dose of FAdV-8b-SK, FAdV-11-1047, and FAdV-2-685 at 14 dph. Broiler progeny 
from broiler breeders vaccinated with either the bivalent live or inactivated FAdV 
vaccine had 98-100% survival (P<0.05) compared to the saline group (23% survival) 
following a lethal challenge of FAdV-8b-SK (A). Whereas 99% survival (P<0.05) was 
observed in broiler progeny compared to saline group (80% survival) following a lethal 
challenge with FAdV-11-1047 (B). After challenge with a heterologous virus, broiler 
progeny from either vaccine group had 100% (P<0.05) survival following a lethal 
challenge of FAdV-2-685 compared to the saline group (95% survival) (C). 
FAdV-8b-SK FAdV-11-1047 A B 
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Figure 2-7: Assessment of maternal antibody mediated protection against 
homologous and heterologous FAdV serotypes. Kaplan-Meier survival estimate of 
progeny following lethal virus challenge at 14 dph (P<0.05), n=90/ group. (A) FAdV-8b-
SK. (B) FAdV-11-1047. (C) FAdV-2-685. 
FAdV-8b-SK FAdV-11-1047 
FAdV-2-685 C 
B A 
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2.5. Discussion 
FAdVs are ubiquitous [18] and chickens often get infected with multiple FAdVs 
[37, 227]. IBH control is challenging because multiple FAdV serotypes of species E 
(FAdV-7, FAdV-8a, FAdV-8b) and species D (FAdV-2, and FAdV-11) cause the disease 
in chicks [3, 189, 195, 241]. It is also known that NAb developed from a monovalent 
vaccine does not cross-protect from infection with a heterologous FAdV species [229]. 
MtAb derived from such vaccines also fail to protect broiler chicks from exposure of 
heterologous FAdVs [229]. Since FAdV-8a and FAdV-8b and FAdV-11 are predominant 
serotypes in Canada [3, 195], we included FAdV-8b and FAdV-11 to develop a bivalent 
FAdV vaccine. 
FAdVs rarely cause disease in adult chickens [189] and were safely used for broiler 
breeder vaccination (FAdV-8b) between 6 to 30 week of age for IBH prevention [229]. 
Since there is a risk of egg-transmission of FAdVs [189, 254, 274] during production, we 
examined the safety of a wild-type FAdV vaccine in broiler breeders by vaccinating them 
at egg-laying age. We observed that a high dose of a wild-type FAdV-8b vaccine which 
otherwise causes very high mortality in chicks [219], did not induce clinical signs or 
pathological changes when given intramuscularly to adult breeders (29 weeks of age). 
However, egg transmission of virus did occur in chicks that were hatched in the first 
week following the broiler breeder vaccination. The results are supported by previous 
studies [272, 273] in which egg transmission is reported within the first week.  Mortality 
can be attributed to viremia occurring at 2 and 3 dpv. Remarkably, no mortality occurred 
in the progeny hatched from the eggs collected during the 2nd and 3rd weeks after the live 
breeder vaccination. This indicated cessation of egg transmission and is likely a response 
to the rising NAb response at 7 dpv [272, 273]. Our data provides strong evidence that 
broiler breeders can be safely vaccinated with wild-type FAdVs at around 16 weeks of 
the age, long before the onset of egg laying. 
FAdV fecal shedding facilitates the horizontal spread of FAdVs [189, 270]. In 
broiler breeders vaccinated at 16 weeks of age, we found that infectious virus shedding 
ceased as early as 14 dpv and viral DNA disappeared at 21 dpv, which coincided with the 
detection of NAb in sera. Our findings are in agreement with previous studies in which 
fecal shedding declined with time in FAdV infected chickens [80, 271].  Apart from 
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humoral immunity, cellular immunity could also play roles in early clearance of virus-
infected cells [279] thus resulting in a significant reduction of infectious virus shedding.  
Live viral vaccines stimulate both cellular and humoral immunity. This is evident by 
chick vaccination with a live FAdV-4 vaccine and survivability of 94.7-100% following 
exposure to a lethal dose of FAdV [260, 300]. Here, we mainly examined the NAb to a 
bivalent live FAdV vaccine in broiler breeders. A single inoculation with 1x104 TCID50 
of a bivalent live FAdV vaccine at 16 weeks of age induced long-lasting (32 weeks) 
broad-spectrum NAb response (2.90 log100.45) against homologues or heterologous 
FAdVs. NAb levels of broiler breeders in either vaccine group at 30 weeks of age were 
3 log10 and were considered protective as 99-100% hatched chicks survived a lethal 
challenge of FAdV-8b-SK, FAdV-11-1047, and FAdV-2 at 14 dph. MtAbs are critical for 
protecting chicks against IBH [279, 294]. In our study, the protection against IBH 
corresponded to the level of MtAbs in chicks of 32.2±0.04% of NAb in breeders at 30 
weeks of age.   
We next examined a bivalent inactivated FAdV vaccine. Historically, inactivated 
autogenous, cell-culture or egg-propagated monovalent and polyvalent FAdV vaccines of 
various doses of viral antigen have shown protection in chicks against FAdVs [192, 294, 
301, 304, 325]. A single vaccination (FAdV-2) of chicks with 1x106 TCID50 induced a 
13-week long NAb response at a level of >6.17 log2 (~2.30 log10) [304]. Here, we 
demonstrated a 32-week long broad-spectrum NAb response in broiler breeders 
vaccinated twice with a bivalent inactivated FAdV vaccine containing 1x106 TCID50 of 
FAdV-8b-SK and FAdV-11-1047. The NAb level was 2.90 log100.45 against the 
vaccine viruses and 2.40 log100.17 against heterologous FAdVs. The chicks had 
21±0.04% MtAb and 98-100% (P<0.05) survival was observed against FAdV-8b-SK, 
FAdV-11-1047 and FAdV-2-685 following virus challenge at 14 dph. Our results agree 
with Alvarado et al. (2007) who observed similar findings with a bivalent autogenous 
FAdV vaccine [294]. 
 
2.6. Conclusions  
Our study demonstrated a long-lasting, broad-spectrum NAb response in broiler 
breeders either by a single vaccination with 1x104 TCID50 of a bivalent FAdV (FAdV-8b-
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SK+FAdV-11-1047) vaccine or by two vaccinations at a dose of 1x106 TCID50 of 
inactivated bivalent vaccine. Broiler breeder vaccination successfully protected chicks 
against IBH by MtAb transfer, which is a common industrial practice for protecting 
chicks against infectious diseases [102]. The induction of cross-protective NAb by the 
vaccines tested in this study strongly supports the idea of eliciting broad-spectrum 
protection against IBH using bivalent or multivalent broiler breeder vaccines. 
Collectively, our data suggest that live and inactivated bivalent vaccines can be used for 
the prevention of IBH in the future. 
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 PREFACE TO CHAPTER 3 
 
In the previous chapter, we have demonstrated a remarkable antibody response to 
inactivated FAdV vaccine adjuvanted with Emulsigen-D in broiler breeders. It is well 
known that adjuvants induce and improve the quality of immune response to inactivated 
vaccines; however, oil-in water adjuvants cause adverse tissue reactions at injection sites 
of a vaccine. Emulsigen-D is an oil-in-water adjuvant commonly use in poultry vaccines 
that has been associated with induction of a good antibody response but tissue necrosis at 
the injection site. Therefore, to minimize tissue reactions and to improve the safety of 
inactivated FAdV vaccine we wanted to explore adjuvant, which induce immune 
responses similar or superior to Emulsigen-D with less tissue reaction. Therefore, we 
have evaluated CpG-ODN to replace Emulsigen-D in our inactivated FAdV vaccine. 
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3.1. Abstract 
IBH is an economically important FAdV disease of broiler chickens worldwide. 
Currently, there is no commercial vaccine available to control IBH in Canada. 
Previously, we have demonstrated the protective efficacy of inactivated live and subunit 
FAdV vaccines against IBH. The objective of this study was to characterize cellular and 
humoral responses in broiler breeders following vaccination with a FAdV-8b-SK vaccine 
adjuvanted with Emulsigen-D or CpG-ODN. Four groups (n=24/group) of broiler 
breeders were vaccinated at 16 weeks of age with FAdV-8b-SK (1x106 TCID50/bird) 
adjuvanted with either 20% Emulsigen-D or 50 µg CpG-ODN. Control groups were 
vaccinated with saline or FAdV-8b-SK with no adjuvant. Groups were boosted at 19 
weeks of age with their respective vaccines. Humoral and cellular immune responses 
were determined by measuring serum IgY and NAb, CD4+:CD8+ T-cell ratio and the 
expression of IL-4 and IFN-γ in peripheral blood. Vaccine efficacy was determined by 
challenging broiler progeny at 14 days post-hatch. As a vaccine adjuvant, CpG-ODN 
induced a 0.20 to 0.30-fold higher IgY antibody response after the booster vaccination 
compared to Emulsigen-D. Both the Emulsigen-D and CpG-ODN adjuvanted groups 
induced NAb ≥2.90 log10 in broiler breeders and were equally protective (99% progeny 
survival, P<0.05) against IBH. The CD4+:CD8++ T-cell ratio increased significantly 
(P<0.05) in the Emulsigen-D adjuvanted group whereas it decreased significantly 
(P<0.05) in the CpG-ODN adjuvanted group. Th-1 and Th-2 type cellular immune 
responses were observed when broiler breeders were vaccinated with FAdV antigens 
adjuvanted with CpG-ODN. Furthermore, FAdV-8b-SK adjuvanted with CpG-ODN 
induced a significantly higher CD8+ T-cell memory response (P<0.05). In summary, 
FAdV-8b-SK adjuvanted with CpG-ODN induced an immune profile to protect their 
progeny against IBH. 
 
3.2.  Introduction 
FAdVs are double-stranded DNA viruses of the family Adenoviridae and genus 
Aviadenovirus [189]. FAdVs are classified into five species (A to E) and twelve serotypes  
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(1-7, 8a, 8b, 9-11) [2]. Some FAdV serotypes are economically important pathogens of 
broiler chickens. Of these, FAdV-2, -7, -8a, -8b and -11 cause IBH, whereas FAdV-4 is 
implicated in HHS and FAdV-1 in gizzard erosions and ulcerations [189]. IBH is the 
most widespread FAdV disease [211]. Its incidence is rising in several continents 
including North America [236, 240, 241, 245, 247, 248]. Unavailability of effective 
vaccines against IBH in North America [221] leaves the industry to rely on the 
application of autogenous vaccines in broiler breeders as a preventative measure in 
endemic areas [3].  
Several types of vaccines (live, inactivated, and subunit vaccines) were developed 
and examined in chickens for their protective efficacy against FAdV diseases (IBH and 
HHS) [221, 279, 294, 304]. Vaccine efficacy can also be improved by formulating with 
different adjuvants. Studies with avian influenza virus and NDV vaccines have shown 
that humoral immunity can be enhanced by mineral-oil-emulsions as adjuvants [331-334] 
or by using modern adjuvants such as interleukins (e.g. IL-18), combination of  
polyriboinosic polyribocytidylic, resiquimod, muramyl dipeptide and levamisole 
(CVCVA5) and CpG-ODN [316, 317, 322]. However, studies that explore cell-mediated 
immunity against FAdV with different adjuvants are rare.   
Emulsigen-D is an oil-in-water emulsion adjuvant used in commercial poultry 
vaccines [335]. Several researchers have evaluated its effects with inactivated vaccines in 
mammals and chickens [279, 318, 336-339]. Studies in mammals have shown that 
Emulsigen-D induces a Th-2 type immune response, which is characterized by IL-4 
secretion by CD4+ T-cells and the production of IgG1 [315, 338, 340].  Like any mineral 
oils, Emulsigen-D causes severe tissue necrosis and severe inflammation at the site of 
vaccination [318, 340]. Severe vaccine reactions cause discomfort, reduced growth and 
downgrading of meat at processing [322, 341]. Hence, it is important to identify safe 
immunogenic adjuvants for poultry vaccines.  
CpG-ODN has been used as a vaccine adjuvant in mammals and avian species 
[315, 318, 319, 324, 333, 340]. Adjuvants such as PECP and avian b-defensins have been 
tested in FAdV vaccine (FAdV-8b) and were demonstrated to be less irritating [221].  
However, no study has examined CpG-ODN as an adjuvant in a FAdV vaccine. CpG-
ODN causes moderate inflammatory cell infiltration with no tissue necrosis at the site of 
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vaccination and has a better safety profile than Emulsigen-D in chickens [318, 342].  
CpG-ODN mimics unmethyated CpG motifs of bacterial DNA and directly stimulates 
immune cells by interacting with intracellular TLR-21 in avian [67] or TLR-9 in 
mammalian cells [324]. This interaction induces various pro-inflammatory cytokines (IL-
1α, IL-1β, TNF-α and INFs) and subsequently induces adaptive immune responses [324]. 
Studies in mice have shown the induction of B-cell differentiation and indirect activation 
of monocytes/macrophages, T-cells and NK cells by CpG-ODN [318, 324]. When CpG 
was administered with inactivated or subunit vaccines, antibody responses increased by 
several folds in both mice and chickens [320, 333, 343, 344]. Antibodies produced by 
vaccines adjuvanted with CpG-ODN in mice are known to persist for more than a year 
[324]. In chickens, CpG-ODN has been shown to induce specific humoral immunity (IgG 
and IgA) against enteric (Escherichia coli) and respiratory pathogens (avian influenza 
virus and NDV) in SPF chicks for 2 weeks post booster vaccination [318-320, 322]. 
However, the effect of CpG-ODN as an adjuvant on cellular immunity in chickens is 
limited only to the study of mRNA expression of a few T helper (Th)-1 type cytokines 
[322]. Therefore, the objective of this study was to characterize T-cell and humoral 
immune responses of a FAdV-8b-SK vaccine adjuvanted with Emulsigen-D or CpG-
ODN in broiler breeders. 
 
3.3. Materials and methods 
3.3.1. Adjuvants, virus and vaccine 
Oligodeoxynucleotides containing CpG motifs (CpG-ODN2007) were purchased 
(Operon Biotechnologies Inc., Huntsville, AL) and reconstituted in TE buffer (pH 8) 
before use. Emulsigen-D was purchased from MVP Technologies (Omaha, NE). The 
FAdV-8b-SK inactivated vaccine (1x106 TCID50/dose) was prepared as described 
previously [279] and was adjuvanted with either Emulsigen-D (20%/dose) or CpG-ODN 
(50 µg/dose).  
 
3.3.2. Animals and experimental design  
Day-old broiler breeders (Ross) were obtained from Aviagen Inc. (Huntsville, 
AL).  Broiler breeders were raised in the Animal Care Unit, Western College of 
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Veterinary Medicine, University of Saskatchewan as per Aviagen guidelines. All 
experiments were conducted according to the Canadian Council of Animal Care 
guidelines and were approved by the campus council on animal use. 
Broiler breeders with no antibodies to FAdVs were divided into 4 groups (n=24) 
which were designated as; Group 1 = FAdV-8b-SK (1x106 TCID50/bird)+20% 
Emulsigen-D; Group 2 = FAdV-8b-SK (1x106 TCID50/bird)+50 µg CpG-ODN; Group 3 
= unadjuvanted FAdV-8b-SK (1x106 TCID50/bird) and Group 4 = saline. Broiler breeders 
were vaccinated intramuscularly at 16 weeks of age and boosted at 19 weeks of age with 
a final volume of 0.5 mL of the respective vaccines. Serum IgY antibodies (n=5) were 
determined at 17, 18, 19, 21 and 23 weeks of age. NAb (n=5) were determined at 17, 18, 
19, 21, 23, 33 and 48 weeks of age. Blood samples (n=5) were collected at 4 days post-
vaccination (dpv) and 9 days post-booster vaccination (dpbv) to measure the CD4+:CD8+ 
T-cell ratio and cytokine expression of T-cells. Eggs were collected from broiler breeders 
between 33 and 37 weeks of age to assess the protective efficacy of the FAdV-8b-SK 
vaccines by FAdV challenge protection of broiler progeny. The FAdV challenge of 
broiler chicks (n=30/group) were conducted by intramuscularly injecting FAdV-8b-SK 
(1x107 TCID50 /bird) at 14 days post-hatch.   
   
3.3.3. Detection of serum IgY antibody by ELISA 
Serum IgY levels were determined by direct ELISA with some modifications 
[345] . Briefly, polystyrene plates were coated with purified FAdV-8b-SK capsid protein 
(purified from FAdV infected cells by the cesium chloride (CsCl) gradient method) with 
coating buffer (R&D Systems, Minneapolis, MN) at a concentration of 7.5 µg/mL and 
incubated overnight at 4 C. The plates were blocked with TBST (1X PBS+0.05% tween-
20+2.5% bovine serum albumin, pH 7.6) for 1.5 h at room temperature. The plates were 
then washed two times with 1X wash buffer (R&D Systems, Minneapolis, MN) and 
incubated with 1:100 diluted sera samples in duplicate for 1.5 h at room temperature. 
Following washing, anti-FAdV-8b-SK IgY antibodies were detected by incubating plates 
with goat-anti-chicken IgY–AP conjugate (Thermo Fisher Scientific, Waltham, MA) for 
1.5 h at room temperature. After washing with wash buffer, the plates were developed 
with 100 µL of ready to use p-nitrophenyl phosphate liquid substrate (Sigma Chemical 
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Co., St. Louis, MO) for 10 min at room temperature. The sample absorbance was 
measured at an optical density (OD) of 405 nm in the spectrophotometer (Molecular 
Devices, Sunnyvale, CA). Positive and negative control sera and blank wells with no sera 
were used as controls.  
 
3.3.4. Detection of neutralizing antibodies by virus neutralization assay 
NAb against FAdV were measured as described previously [279]. Briefly, two-
fold serial dilutions of heat-inactivated sera samples (30 min at 56 C) were mixed with 
200 TCID50 of FAdV-8b-SK in triplicates. The samples were incubated for 1 h at 37 C in 
5% CO2. The samples were then transferred to 96-well plates containing 5x10
4 freshly 
prepared leghorn male hepatoma cells per well from the highest dilution to least dilution 
and incubated for 7 days to visualize the cytopathic effects.  
 
3.3.5. Determination of CD4+:CD8+ T-cell ratio in peripheral blood 
mononuclear cells 
Heparinized blood was diluted 1:1 with 1X PBS, layered over histopaque-1077 (Sigma-
Aldrich, Oakville Ontario) and centrifuged at 2000 rpm for 15 min at 10  C to separate 
peripheral blood mononuclear cells (PBMC). PBMC were washed twice with 5 mL 1X 
PBS to remove histopaque. An aliquot of 50 µL/sample was stained with anti-chicken 
CD4-PE and anti-chicken CD8-FITC conjugate (1 µL of each/sample) for 30 min on ice. 
The samples were washed twice and 300 µL of 1X PBS (pH 7.6) was added to each for 
flow cytometry (CytoFlex Flow cytometer, Beckman Coulter, Mississauga, Ontario). The 
results were analyzed by using FlowJO software (TreeStar; Ashland, OR). 
 
3.3.6. Quantification of cytokine expression in peripheral blood mononuclear 
cells 
Intracellular IFN-γ and IL-4 expression in CD4+ and CD8+ T-cells in PBMC was 
determined by flow cytometry. Briefly, 5x105 PBMC were seeded into 96-well round 
bottom plates in DMEM: F-12 supplemented with 5% fetal bovine serum, 2mM 
glutamine, 20 mM HEPES and 1:1000 gentamicin (100 µL of 50 mg/mL/100 mL of 
media). PBMC were stimulated in vitro for 8 h either with Concanavalin-A (5 µg/mL) as 
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a positive control or FAdV-8b-SK capsid protein (10 µg/mL) formulated with Golgi-stop 
(4 µL/6 mL). Following incubation, the cells were washed twice with 1X PBS and 
stained for anti-chicken CD4 and CD8 T-cell markers as described above. For 
intracytoplasmic staining of IL-4 and IFN-γ, cells were fixed by adding 250 µL 
permeabilization solution/sample (BD Biosciences, San Jose, CA) during vortexing and 
incubating for 20 min on ice. Following fixation, cells were incubated for 30 min on ice 
with biotinylated-rabbit-anti-chicken IL-4 (LS Bio, Seattle, WA) or rabbit-anti-chicken 
IFN-γ (Thermo Fisher Scientific, Waltham, MA) primary antibodies. The samples were 
washed twice with 1X BD wash-buffer and incubated for 30 min on ice with 
Streptavidin-PE/CY5.5 (BioLegend, San Diego, CA) and goat-anti-rabbit IgG-PE/CY5.5 
(Thermo Fisher Scientific, Waltham, MA) secondary antibodies. Subsequently, the cells 
were washed and resuspended in 300 µL for flow cytometry. Positive, negative and 
isotype controls were processed simultaneously.  
 
3.3.7. Statistical analysis  
The experimental data was analyzed in Prism 7 (Graph Pad Inc. San Diego, CA). 
Broiler breeder antibody responses (OD values), cytokine expression on T-cells and 
CD4+:CD8+ T-cell ratio were compared among the groups using one-way ANOVA and 
either Dunnett’s or Bonferroni’s post-test correction. The normality of the data was 
analyzed with Shapiro-wilk test before using ANOVA. The median survival time in the 
broiler progeny following virus challenge was compared using Mantel-cox (Log-rank) 
test. The results were considered statistically significant at P<0.05. 
 
3.4. Results  
3.4.1. Serum IgY antibody and neutralizing antibody response in broiler 
breeders 
Serum IgY levels in broiler breeders were determined up to 6 weeks post-
vaccination by ELISA. No significant differences were found in OD values (P<0.05) of 
serum in broiler breeders vaccinated with FAdV-8b-SK with no adjuvant and saline 
group at any of the time points. IgY antibodies were detected in broiler breeders 
vaccinated with FAdV-8b-SK adjuvanted with either Emulsigen-D or CpG-ODN at 18 
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weeks of age.  The mean OD values in the FAdV-8b-SK adjuvanted with Emulsigen-D 
and CpG-ODN groups at 18 weeks of age were 0.30±0.23 and 0.31±0.37, respectively 
(Figure 3-1A). The mean OD values in the FAdV-8b-SK adjuvanted with Emulsigen-D 
or CpG-ODN groups at 19 weeks of age (booster vaccination) were 0.45±0.41 and 
0.37±0.57 respectively. At 2 to 3 weeks after the booster vaccination (i.e. 21 to 22 weeks 
of age) the serum OD values became significantly higher (P<0.05) in broiler breeders 
vaccinated with the FAdV-8b-SK vaccines adjuvanted with either Emulsigen-D or CpG-
ODN compared to broiler breeders that were vaccinated with FAdV-8b-SK with no 
adjuvant or saline.  The serum OD values in the FAdV-8b-SK adjuvanted with 
Emulsigen-D at 21 and 23 weeks of age were 1.10±0.30 and 0.86±0.00, respectively 
while serum OD values inFAdV-8b-SK adjuvanted with CpG-ODN were 1.36±0.07 and 
1.18±0.12 respectively.  
NAbs against FAdVs were measured at 17, 18, 19, 21, 23, 33 and 48 weeks of 
age. No NAb were detected in broiler breeders vaccinated with FAdV-8b-SK with no 
adjuvant or saline. NAbs became detectable at 19 weeks of age in broiler breeders 
vaccinated with FAdV-8b-SK adjuvanted with either Emulsigen-D or CpG-ODN (Figure 
3-1B). NAb levels in the groups vaccinated with FAdV-8b-SK adjuvanted with either 
Emulsigen-D or CpG-ODN were significantly higher (P<0.05) than the FAdV-8b-SK 
with no adjuvant or saline groups at 19, 21, 23, 33 and 48 weeks of age. NAb (mean±SD) 
levels of broiler breeders vaccinated with FAdV-8b-SK adjuvanted with Emulsigen-D 
and FAdV-8b-SK adjuvanted with CpG-ODN at 19 weeks of age were 2.90 log10±0.30 
and 2.90 log10±0.00, respectively.  Both the FAdV-8b-SK adjuvanted with Emulsigen-D 
and FAdV-8b-SK adjuvanted with CpG-ODN groups reached their peak mean NAb titers 
at 23 weeks of age. At 23 weeks of age, NAb titers were 3.10 log10±0.32 (FAdV-8b-SK 
adjuvanted with Emulsigen-D) and 3.10 log10±0.36 (FAdV-8b-SK adjuvanted with CpG-
ODN). At 48 weeks of age, the mean NAb in the FAdV-8b-SK adjuvanted with CpG-
ODN group were 3.40 log10± 0.46 while in the FAdV-8b-SK adjuvanted with Emulsigen-
D group mean NAb were 3.10 log10±0.42.   
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Figure 3-1: Serum IgY and neutralizing antibody levels against FAdV-8b-SK 
adjuvanted with Emulsigen D or CpG-ODN, FAdV-8b-SK with no adjuvant and 
saline in broiler breeders following vaccination. (A) Serum IgY against FAdV-8b-SK 
(mean OD±SD), n=5, P<0.05, ****=0.0001, One-way ANOVA with Bonferroni’s post-
test (B) NAb against FAdV-8b-SK (mean ±SD) n=5, P<0.05, * = 0.003 (C) Survival of 
broiler chickens following homologus challenge of FAdV-8b-SK (Kapan-Meier survival 
estimates) FAdV-8b-SK at 14 days post-hatch. (P<0.05), Mantel cox (Log-rank) test, 
n=30. P<0.05. 
 
3.4.2. Progeny protection 
Maternal antibody mediated protection was confirmed by directly challenging the 
chicks with a lethal dose (1x107 TCID50/bird) of FAdV-8b-SK at 14 dph. Approximately, 
99% survival (P<0.05) was observed in the chicks hatched from broiler breeders 
vaccinated with FAdV-8b-SK vaccine adjuvanted with Emulsigen-D or CpG-ODN 
compared to the progeny from broiler breeder parents vaccinated with saline (P<0.05) 
(Figure 3-2).  
 
A B 
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Figure 3-2: Challenge protection study in broiler progeny at 14 days post-hatch 
Survival of broiler chickens following homologus challenge of FAdV-8b-SK (Kapan-
Meier survival estimates) FAdV-8b-SK at 14 days post-hatch. (P<0.05), Mantel cox 
(Log-rank) test, n=30. P<0.05. 
  
3.4.3. CD4+:CD8+ T-cell ratio in peripheral blood mononuclear cells 
Cellular immunity of broiler breeders vaccinated with FAdV-8b-SK adjuvanted 
with Emulsigen-D or CpG-ODN was evaluated by measuring the ratio of CD4+:CD8+ T-
cells in PBMC. At 9 dpv, the mean CD4+:CD8+ T-cell ratios were 1.27, 0.82, 1.04 and 
0.82 in broiler breeders vaccinated with FAdV-8b-SK adjuvanted with Emulsigen-D, 
FAdV-8b-SK adjuvanted with CpG-ODN, FAdV-8b-SK with no adjuvant and saline 
respectively (Figure 3-3A and B). The mean CD4+:CD8+ T-cell ratio was significantly 
higher (P<0.05) in broiler breeders vaccinated with FAdV-8b-SK adjuvanted with 
Emulsigen-D or FAdV-8b-SK with no adjuvant compared to the saline control. At 24 
dpv, the mean CD4+:CD8+ T-cell ratios were 1.35, 0.92, 1.06 and 1.00 in broiler breeders 
vaccinated with FAdV-8b-SK adjuvanted with Emulsigen-D, FAdV-8b-SK adjuvanted 
with CpG-ODN, FAdV-8b-SK with no adjuvant and saline respectively. At 24 dpv, the 
CD4+:CD8+ T-cell ratio was significant (P<0.05) in the broiler breeders that were 
vaccinated with FAdV-8b-SK adjuvanted with Emulsigen-D.  
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Figure 3-3: CD4+:CD8+ T-cell ratio in peripheral blood mononuclear cells. (A) 
CD4+:CD8+ T-cell ratio at 9 and 24 days post-vaccination. n=5, P<0.05, *** = 0.001, ** 
= 0.01, One-way ANOVA with Dunnett’s post-test (B) Flow-cytometric profile at 9 dpv 
in broiler breeders vaccinated with FAdV-8b-SK vaccine adjuvanted with 20% 
Emusigen-D, FAdV-8b-SK adjuvanted with 50 µg CpG-ODN, FAdV-8b-SK with no 
adjuvant and saline. The percentage of cell populations were calculated on 25000 events. 
The mean CD4+:CD8+ T-cell ratio elevated in FAdV-8b-SK with no adjuvant and FAdV-
8b-SK adjuvanted with Emulsigen-D, and it lower in FAdV-8b-SK adjuvanted with CpG-
ODN. 
  
3.4.4. Cytokine expression on peripheral blood mononuclear cells 
IFN-γ and IL-4 expression in CD4+ T-cells and IFN-γ expression in CD8+ T-cells 
in the PBMC of broiler breeders was analyzed to categorize the pattern of immune 
response supported by these adjuvants. Figures  
B 
A 
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Figure 3-4A and B show the percentages of IL-4 and IFN-γ expressing CD4+ T-
cells in various groups at 9 dpv. Broiler breeders vaccinated with FAdV-8b-SK without 
an adjuvant had a significantly higher percentage of CD4+ T-cells that expressed IFN-γ 
(1.91%) compared to CD4+ T-cells that expressed IL-4 (0.52%). The percentage of CD4+ 
T-cells which expressed IL-4 and IFN-γ were increased significantly (P<0.05) in FAdV-
8b-SK vaccine adjuvnated with Emulsigen-D or CpG-ODN. The mean IL-4 expression in 
CD4+ T-cells was 5.53% and 3.56% in broiler breeders vaccinated with FAdV-8b-SK 
adjuvanted with Emulsigen-D or CpG-ODN compared to 0.52% in the FAdV-8b-SK 
group with no adjuvant. The mean CD4+ T-cells with IL-4 expression was significantly 
higher (P<0.05) in the FAdV-8b-SK adjuvanted with Emulsigen-D group compared to 
the FAdV-8b-SK adjuvanted with CpG-ODN. Similarly, the percentage of CD4+ T-cells 
expressing IFN-γ significantly increased (P<0.05) in broiler breeders vaccinated with 
FAdV-8b-SK adjuvanted with Emulsigen-D or CpG-ODN compared to the FAdV-8b-SK 
group with no adjuvant. The mean CD4+ T-cells expressing IFN-γ was 3.51% and 4.25% 
in broiler breeders vaccinated with FAdV-8b-SK adjuvanted with Emulsigen-D or CpG-
ODN compared to 1.91% in the FAdV-8b-SK group with no adjuvant. The mean CD4+ 
T-cells expressing IFN-γ was significantly higher (P<0.05) in the FAdV-8b-SK 
adjuvanted with CpG-ODN group compared to the FAdV-8b-SK adjuvanted with 
Emulsigen-D group.  
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Figure 3-4: Cytokine expression in peripheral blood mononuclear cells at 9 days 
post-vaccination.  (A) Percentage of IL-4 and IFN-γ expressing CD4+ T-cells. n=5, 
P<0.05, **** =0.0001, ***= 0.001, One-way ANOVA with Bonferroni’s post-test (B) 
Fow-cytometric profile of IL-4 and IFN-γ expressing CD4+ T-cells in broiler breeders 
vaccinated with FAdV-8b-SK adjuvnated with  20% Emulsigen-D, FAdV-8b-SK 
adjuvanted with 50 µg CpG-ODN and FAdV-8b-SK with no adjuvant. (n=5). The 
percentage was calculated from 25000 events. Percentage of IL-4 and IFN-γ expressing 
CD4+ T-cells were evelated in the FAdV-8b-SK adjuvnated with Emulsigen-D or CpG-
ODN. IL-4 expressing CD4+ T-cells predominated with Emulsigen-D and the percentage 
of IL-4 and IFN-γ expressing CD4+ T-cells predominated with CpG-ODN. 
A 
B 
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After the booster vaccination, the mean percentage of CD8+ T-cells expressing 
IFN-γ increased significantly (P<0.05) in broiler breeders vaccinated with FAdV-8b-SK 
adjuvanted with Emulsigen-D (2.63%) or FAdV-8b-SK adjuvanted with CpG-ODN 
(5.54%) compared to the FAdV-8b-SK with no adjuvant group (2.01%) (Figure 3-5A and 
B). The mean percentage of CD8+ T-cells expressing IFN-γ was significantly higher in 
the FAdV-8b-SK adjuvanted with CpG-ODN group compared to the FAdV-8b-SK 
adjuvanted with Emulsigen-D group.  
 
Figure 3-5: Cytokine expression on peripheral blood mononuclear cells at 24 days 
post- vaccination.  (A) Percentage of IFN-γ expressing CD8+ T-cells. n=5, P<0.05, **** 
= 0.0001, One-way ANOVA with Bonferroni’s post-test (B) Flow-cytometric profile of 
IFN-γ expressing CD8+ T-cells in broiler breeders vaccinated with inactivated FAdV-8b-
SK vaccine adjuvanted with 20% Emulsigen-D, FAdV-8b-SK adjuvanted with 50 µg 
CpG-ODN and FAdV-8b-SK with no adjuvant. (n=5). The percentage of cells were 
calculated from 25000 events. The percentage of IFN-γ expressing CD8+ T-cells 
predominated in the FAdV-8b-SK adjuvanted with CpG-ODN.Discussion 
A 
B 
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Formulation of vaccines with adjuvants to enhance the efficacy is important in 
mammalian and avian vaccinology. Adjuvants enhance and modulate immune responses  
to inactivated vaccine antigens [346] and improve their efficacy by inducing pathogen-
specific antibodies in blood and mucosal surfaces [333]. Certain adjuvants can promote 
development of cellular immunity to enhance vaccine efficacy against pathogens [346]. 
Some vaccine efficacy studies conducted in chickens using avian influenza and NDV 
vaccines have examined the effects of Emulsigen-D and CpG-ODN on humoral 
immunity by examining IgY and and IgM in serum and IgA in mucosal surfaces [318-
320, 322, 333]. In this study, we have characterized cell-mediated immune responses by 
quantifying CD4+ T-cells and CD8+ T-cells and humoral immune responses by IFN-γ and 
IL-4 production following FAdV-8b-SK vaccines adjuvanted with Emulsigen-D or CpG-
ODN in broiler breeders. 
Humoral immunity plays a critical role in the neutralization of FAdVs in blood 
and internal organs [189, 279, 294]. Maternal antibodies are able to neutralize FAdV and 
prevent the development of clinical disease of IBH in broiler chickens [102, 294]. Hence, 
induction of a robust and long-lasting humoral immunity in broiler breeders is an 
important prerequisite for an effective FAdV vaccine program. We investigated IgY and 
NAb in serum against a FAdV-8b-SK vaccine and the correlation to FAdV challenge 
protection in broiler chickens.  We did not detect any antibodies against FAdVs when the 
FAdV-8b-SK vaccine was formulated with no adjuvant. This observation could be 
associated with two possibilities; a lower sensitivity of our assay (ELISA) or an 
insignificant amount of antibody production with FAdV-8b-SK vaccine with no adjuvant. 
Between adjuvants used in FAdV vaccine, IgY levels were low in FAdV-8b-SK 
adjuvanted with CpG-ODN compared to FAdV-8b-SK adjuvanted with Emulsigen-D 
group for initial 3 weeks following vaccination. However, IgY levels were 0.20 to 0.30-
fold higher in FAdV-8b-SK adjuvanted with CpG-ODN group compared to the FAdV-
8b-SK adjuvanted with Emulsigen-D group after booster vaccination. Similar 
observations were reported earlier in chickens vaccinated with an E. coli vaccine 
adjuvanted with CpG-ODN compared to an E. coli vaccine adjuvanted with Emulsigen-D 
after booster vaccination [318]. Similarly, a remarkable increase in IgY was 
demonstrated following booster vaccination in chickens that were vaccinated with avian 
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influenza virus or Newcastle disease virus vaccines adjuvanted with CpG-ODN [320, 
333].  
Antibodies detected by ELISA do not correlate with protection of broiler chickens 
against IBH [331]. In contrast, NAb against FAdVs are correlated with protection [279, 
294]. Group that were vaccinated with FAdV-8b-SK with no adjuvant did not have NAb 
against FAdVs which corroborated with ELISA readings for IgY antibodies. Neutralizing 
antibody titers against FAdV in broiler breeders vaccinated with FAdV-8b-SK 
adjuvanted with Emulsigen-D or CpG-ODN were similar until 48 weeks of age. 
However, at 48 weeks of age, NAb titers became significantly higher in broiler breeders 
vaccinated with FAdV-8b-SK adjuvanted with CpG-ODN compared to the FAdV-8b-SK 
adjuvanted with Emulsigen-D group (3.40 log10±0.46 vs 3.10 log10±0.42) (P<0.05). In 
this study, the mean NAb levels at all time points tested in either vaccine group were 
≥2.90 log10 and were similar (≥3.0 log10) to another vaccine efficacy study conducted 
using large group of birds  (n=300 birds/group) [347]. In order to confirm the protective 
ability of NAb, broiler chickens were challenged with FAdV-8b-SK at 14 days of age. As 
expected, broiler chickens from broiler breeders vaccinated with FAdV-8b-SK-
adjuvanted with Emulsigen-D or CpG-ODN were protected against FAdV challenge 
(99% survival, P<0.05).  
In addition to characterization of humoral immune responses of FAdV-8b-SK 
vaccines adjuvanted with Emulsigen-D or CpG-ODN, we evaluated T-cell responses in 
broiler breeders. Cellular mediated immunity helps in clearing virus infected cells from 
the host [348] and also aids in the development of humoral immunity [349]. Although 
Emulsigen-D and CpG-ODN were used as vaccine adjuvants against AIV and NDV in 
chickens [319, 320, 322] cell mediated immunity was not well characterized. Unlike 
antibody responses, our FAdV-8b-SK vaccine with no adjuvant induced a T-CD4+ T-cell 
response (elevated CD4+:CD8+ T-cell ratio). The CD4+ T-cell response increased 0.22-
fold higher in broiler breeders vaccinated with FAdV-8b-SK adjuvanted with Emulsigen-
D. Interestingly, FAdV-8b-SK adjuvanted with Emulsigen-D increased only CD4+ T-
cells in contrast; FAdV-8b-SK adjuvanted with CpG-ODN induced both CD4+ and CD8+ 
T-cells. Moreover, CD8+ T-cell response was predominated in FAdV-8b-SK adjuvanted 
with CpG-ODN compared to CD4+ T-cell response. Induction of CD 8+ T-cells were also 
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observed in mice vaccinated with a subunit hepatitis B vaccine and tetanus toxoid 
adjuvanted with CpG-ODN as well as in pigs vaccinated with a rcC1 cycticercosis 
vaccine adjuvanted with CpG-ODN [343, 350]. Hence, induction of CD8+ T-cells may be 
an inherent feature of CpG-ODN as an adjuvant irrespective of the host species.  
In addition to measuring T-cell responses by CD4+:CD8+ T-cell ratio, cytokine 
secretion by T-cells was explored to determine the effect of adjuvants in the development 
of type cellular immunity. Early in the development of adaptive immunity, naïve CD4+ 
T-cells differentiate into Th-1 or Th-2 type cells following interaction with antigen 
presenting cells and commit to a lineage (Th-1 or Th-2). Hence, we determined IL-4 and 
IFN-γ expression of CD4+ T-cells at 9 dpv. CD4+ T helper subsets can be identified by 
their cytokine profile [349]. IFN-γ, IL-2, IL-6 and IL-12 are the hallmark of Th-1 type 
immunity, whereas, IL-4, IL-5 and IL-10 and IL-13 indicate Th-2 type immunity [349]. 
In this study, we selected IFN-γ and IL-4 cytokines to identify Th-1 and Th-2 type CD4+ 
T-cells. Enhanced IL-4 secretion was documented in chickens following vaccination with 
FAdV-4 adjuvanted with mineral-oil adjuvant [193], but no information is available for 
the effect of Emulsigen-D on the cytokine profile. Similarly, the Th-1 type immune 
response after vaccination with an avian influenza virus vaccine adjuvanted with CpG-
ODN have documented an mRNA expression [322] however, mRNA expression may 
correlate with protein expression. Here, we have measured intracellular cytokine 
expression in PBMC of broiler breeders. We noticed that FAdV-8b-SK vaccine with no 
adjuvant induced predominantly a Th-1 type response (IFN-γ producing CD4+ T-cells). 
Formulation of FAdV-8b-SK with Emulsigen-D or CpG-ODN as an adjuvant induced 
Th-1 (CD+ T-cells secreting IL-4) or Th-2 (CD+ T-cells secreting IFN-γ) type immune 
responses in broiler breeders. Interestingly, the immune response was polarised towards a 
Th-2 type in FAdV-8b-SK adjuvanted with Emulsigen-D by increased IL-4 producing 
CD4+ T-cells, whereas the immune response was polarised towards Th-1 type immune 
response in FAdV-8b-SK adjuvanted with CpG-ODN by producing IFN-γ expressing 
CD4+ T-cells.  
After the booster vaccination, the objective was to measure the memory response 
in broiler breeders to the FAdV vaccine. Hence, we measured the number of CD8+ T-
cells expressing IFN-γ. Following booster vaccination, a strong CD8+ T immune 
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response was noted in the FAdV-8b-SK adjuvanted with CpG-ODN compared to the 
FAdV-8b-SK vaccine adjuvanted with Emulsigen-D. Increased induction of CD8+ T-cell 
response was correlated with a higher percentage of Th-1 type CD4+ T-cells in FAdV-8b-
SK adjuvanted with CpG-ODN. Th-1 type CD4+ T-cells play an important role in 
priming and memory response of CD8+ T-cells [324, 351]. It is evident that FAdV-8b-SK 
vaccine with no adjuvant or addition of CpG-ODN favors a Th-1 type immune response, 
whereas the immune response is skewed towards a Th-2 type immunity by the addition of 
Emulsigen-D. It is also apparent that the FAdV-8b-SK vaccine adjuvanted with CpG-
ODN had better immune memory cell development. 
It is summary, both FAdV-8b-SK vaccines adjuvanted with Emulsigen-D or CpG-
ODN had strong, durable and protective humoral immunity in broiler breeders and this 
humoral immunity passively transferred to their progeny to protect them against IBH. We 
also observed Th-1 and Th-2 type immune responses with FAdV-8b-SK antigens 
adjuvanted with CpG-ODN.  . Moreover, FAdV-8b-SK adjuvanted with CpG-ODN had 
better immune memory cell development by the production of CD8+ T-cell responses. 
Furthermore, since no necrosis at the injection site was observed with vaccines 
formulated with CpG-ODN [318, 342], CpG-ODN seems to be better choice of adjuvant 
for a FAdV-8b-SK vaccine. 
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PREFACE TO CHAPTER 4 
 
There are advantages and disadvantages of live and inactivated vaccines. For 
safety reasons and in the absence of suitable live vaccines, inactivated vaccines are 
preferred. Moreover, inactivated vaccines are main components of prime-boost 
vaccination programs to boost the immunity following priming with live viruses. In 
previous chapters, we have propagated FAdVs in cell culture systems to make live and 
inactivated FAdV vaccines. We observed that FAdV-11 grows to a lower titer of 1x106 
TCID50/mL in LMH cells compared to FAdV-8b which could give a higher titer of 1x10
9 
TCID50 per mL (personal observation). We also noticed that it takes a longer time (>100 
hours) to attain 1x106 TCID50/mL for FAdV-11 compared to 72 to 96 hours for FAdV-8b 
when LMH cells were infected at an equal multiplicity of infection with respective 
viruses. This can be a problem in the mass production of the inactivated vaccine antigens 
for inactivated vaccines. In such cases, subunit vaccines can be an alternative.  
Subunit vaccines are small immunogenic microbial proteins that can elicit 
protective immune responses following formulation with an adjuvant. In the next chapter, 
we have investigated immunogenicity and protective efficacy of recombinant fiber and 
fiber-knob subunit antigens and virus-like-particles (VLPs) of FAdV-8b-SK as a breeder 
vaccine. 
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4.1. Abstract 
IBH is one of the most economically important diseases in the broiler chicken 
industry. Several serotypes of FAdVs can cause IBH; among them, serotype FAdV-8b is 
one of the emerging serotypes associated with IBH cases in Canada. In the present study, 
we evaluated FAdV-8b-SK VLPs and two recombinant FAdV-8b-SK fiber proteins 
(expressed in E. coli) as potential broiler breeder vaccines against IBH. For assessing the 
immunogenicity of vaccines, we investigated both humoral and cellular immunity. The 
humoral immunity was evaluated by determining the total IgY levels and neutralizing 
antibodies in serum at 14, 28, 35 and 60 days post-vaccination (dpv). The cellular 
immunity was examined using flow cytometry by determining the CD4+:CD8+ T-cell 
ratio change in peripheral blood after the booster vaccination. The protective effect of 
vaccines was tested through progeny challenges of 14 day-old broiler chicks 
(n=30/group), by exposing them to a virulent FAdV-8b-SK virus (1x107 TCID50, FAdV-
8b-SK). Although total IgY levels were comparable in all groups, the neutralizing 
antibody response at 35 and 60 dpv was significantly (P<0.05) higher in the broiler 
breeders immunized with FAdV-8b-SK VLPs, followed by FAdV-8b-SK fiber vaccine, 
compared to FAdV-8b-SK fiber-knob vaccine. Moreover, FAdV-8b-SK VLPs and 
FAdV-8b-SK fiber (but not FAdV-8b-SK fiber-knob vaccine) efficiently elicited the cell-
mediated immune response as evidenced by statistically significant (P<0.05) CD8+ T-cell 
proliferative response in broiler breeders four days after the booster vaccination. Unlike 
the FAdV-8b-SK fiber-knob, FAdV-8b-SK VLPs, and FAdV-8b-SK fiber vaccinated 
broiler breeders were able to transfer a substantial amount (28.4±90%) of MAbs to their 
progenies. The progeny challenge revealed that MAbs provided 100% and 82.7% 
protection in chicks from FAdV-8b-SK VLPs, and FAdV-8b-SK fiber vaccinated broiler 
breeders, respectively. Collectively, our data suggest that the FAdV-8b-SK subunit 
vaccine-induced MAbs efficiently and protected broilers against clinical IBH.  Broiler 
breeder vaccination with subunit vaccines is a potential approach for the control of IBH.  
 
4.2. Introduction  
FAdVs are non-enveloped, dsDNA viruses of the genus Aviadenovirus in the 
family Adenoviridae [2], which often cause disease in 2 to 5 weeks old broilers [189]. 
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They are classified into five species (A-E) and twelve serotypes (FAdV -1 to -7, -8a, -8b, 
-9 and -11) [2, 189, 270, 293]. FAdV-1 and FAdV-4 are associated with gizzard erosions 
and ulcerations and HHS, respectively [189]. Several serotypes, like FAdV-2, FAdV-8a, 
FAdV-8b, and FAdV-11 have been associated with IBH [3, 161, 215, 218, 229, 352, 
353], which is a worldwide problem. FAdV-8b is one of the emerging serotypes of 
FAdVs. The disease is characterized by liver necrosis, hemorrhage and basophilic 
intranuclear inclusion bodies in the hepatocytes [219, 229, 231]. Mortality associated 
with the disease ranges from 10% to 30% [39, 217]. To control IBH in broiler progenies, 
broiler breeders are vaccinated with autogenous vaccines [3, 221, 294]. Passive immunity 
through MAb transfer protects against infectious diseases during the first few weeks of 
the neonatal life. Despite the use of autogenous vaccines, though the incidence of the 
FAdV diseases have declined [161], and the broiler chicken industry still incur 
considerable economic losses. This is due to sporadic outbreaks of IBH which are 
attributed to exposure to heterologous serotypes. Hence, the development of an effective 
and safe IBH vaccine is highly desired.  
Among the various vaccine types, subunit or VLP based vaccines are potential 
alternatives to live or inactivated vaccines due to their safety, and ease of production on a 
large scale. A subunit vaccine is a recombinant small immunogenic component of a 
microorganism, which elicits a protective immune response in combination with an 
adjuvant [352]. VLP is a type of subunit vaccine, which mimics the natural virus 
conformation, but lacks the infectious genome [354, 355]. VLPs have been developed for 
poultry pathogens such as NDV [356], however, these vaccines remain in preliminary 
stages of development. Although, several fowl adenoviral proteins including hexon, 
penton and fiber capsid have been identified as potential subunit vaccine antigens [43, 
221, 306], FAdV fiber protein has been proposed as the most suitable immunogen for 
subunit vaccine development [43]. This is due to its ability to induce neutralizing 
antibody responses [181, 309] as well preventing clinical disease (e.g., HHS) in chicks 
upon exposure to a lethal virus dose [43]. All previous studies conducted on subunit 
FAdV vaccines against FAdVs were carried out in chicks as a broiler vaccine [43, 306]. 
Evaluation of subunit vaccines for use in broiler breeder vaccination programs has not 
previously been reported. 
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Therefore, in the present study we investigated the effectiveness of vaccination of 
broiler breeders with VLPs and subunit-based vaccines in preventing IBH in their 
progeny. We compared the effectiveness of VLPs, recombinant fiber, or recombinant 
fiber-knob vaccines through progeny challenge.  
 
4.3. Material and methods 
4.3.1. Virus, cell line and antibodies 
A FAdV (FAdV-8b-SK) isolated from a clinical case of IBH in a broiler chicken 
flock in Saskatchewan was used in this study. Based on the loop-1 hexon protein 
sequence, it had 93.9% amino acid similarity to FAdV-8a-T8-A (which was later 
suggested to be renamed as FAdV-8b [204, 212]) and FAdV-8b strain 764 [292]. Due to 
its genetic relatedness to FAdV-8b strains (Figure 4-1), we named this isolate as FAdV-
8b-SK.  
 
Figure 4-1: Phylogenetic tree analysis of FAdV-8b-SK. Sequences of other isolates of 
FAdV were extracted from the Genbank. Jukes-Cantor genetic distance model with Boot 
strap neighbor-joining method with 1000 replicates was used to construct the tree with 
the Geneious 9.1.5 software. 
A LMH cell line was (ATCC #CRL-2117) used to propagate FAdVs DMEM: F-
12 (Thermo Fisher Scientific) containing 20 mM HEPES (pH=7.2), 2 mM glutamine, 
1:1000 gentamicin (100 µL of 50 µg/mL per 100 mL of media) and 10% fetal bovine 
  
80 
  
serum was used to propagate LMH cells. Anti-6x-His epitope tag mouse monoclonal 
antibody (Thermo Fisher Scientific), and Alkaline Phospahte conjugate Goat anti-mouse 
IgG (H+L) polyclonal antibody (ThermoFisher Scientific) were used for detection of 
recombinant expressed proteins.  
 
4.3.2. Purification of fowl adenovirus (FAdV-8b-SK) virus-like particles 
The empty capsids of FAdV-8b-SK were conventionally purified from a cesium 
chloride (CsCl) density gradient method. Hereafter, we referred to it as VLPs, as they 
lack the genome. Generation of VLPs were confirmed by transmission electron 
microscopy. Briefly, FAdV-8b-SK was grown in LMH cell line in T175 flasks (Corning). 
The cells were infected at a multiplicity of infection of 1 and incubated at 37 C with 5% 
CO2 and harvested when 80% or more cells were showing adenovirus-specific cytopathic 
effect. The lysates were freeze-thawed five times. Later, 1.5 mL of sodium deoxycholate 
(5%) was added per 5 mL of lysate and incubated for 30 min at room temperature. Once 
the suspension became viscous, it was incubated with 2 M MgCl2 and DNase-I solution 
for 1 h at 37 C. The cell lysate was spun at 4000 rpm in a tabletop centrifuge for 30 min. 
The supernatant was loaded onto CsCl (1.25/1.34 g/mL) cushion and spun at 35,000 rpm 
for 24 h at 10 C. The capsid (upper band) and virus (lower band) was aspirated separately 
and dialyzed in 0.1 M Tris-HCl (pH8) three times for 8 hr each. The capsid protein 
concentration was measured by Bradford assay in 96-well plate as per manufacturer’s 
instructions. The optical density was read in SoftmaxPro5 data acquisition and analysis 
software (Molecular Devices, LLC) at 590 nm. A sample of the dialyzed protein was 
subjected to transmission electron microscopy to identify the morphology of VLPs. In 
addition, another sample of the VLP was passaged in LMH cells two times to confirm 
non-infectiousness of the VLP protein. 
 
4.3.3. Transmission electron microscopy  
Samples for negative staining and transmission electron microscopy were 
processed using standard techniques as described before [357]. Briefly, 300-mesh copper 
carbon/formvar-coated grid was floated on 20 μL droplet of sample for 2 min. Then, the 
grid was rinsed through two water droplets for 30 sec with each drop. Finally, the grid 
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was floated on a 0.5% phosphotungstic acid for 1 min and drew off excess and allowed 
the thin layer to dry on grid and the grids were examined under transmission electron 
microscopy. 
 
4.3.4. Cloning of fiber and fiber-knob gene of FAdV-8b-SK 
LMH cells were grown in six well plates and infected with FAdV-8b-SK at 1 
multiplicity of infection. Then, after 36 h of infection, total DNA was extracted using a 
viral DNA isolation kit (Qiagen) as per the manufacturer’s protocol. FAdV DNA that 
encoded full fiber or fiber-knob was amplified from the extracted DNA using primers 
shown in the Table 4-1. PCR was performed using cycling conditions of initial 
denaturation at 94 C for 2 min, and 40 cycles of denaturation at 94 C for 30 sec, 
annealing at 62 C, extension at 72 C followed by a final extension at 72 C for 5 min.  To 
express the full-length fiber protein, coding approximately 62 kDa protein, a 1575 bp 
long fiber gene of FAdV-8b-SK was amplified in a standard polymerase reaction using 
Accustart Taq polymerase (Quanta Biosciences) with primers F1 and F2.   
 
Table 4-1: Primer used for cloning of fiber and fiber-knob of FAdV-8b-SK 
Primer ID 5’-3’ Sequence Reference 
F1 AAGCATGCATGGCGACCTCIACTCCTCA This study 
F2 ATTAAGCTTTTACGGAGCGTTGGCTGTGCTTAGGG This study 
F3 CGGGATCCTATTTCACGTTCTGGGTAGG This study 
F4 ATTAAGCTTTTACGGAGCGTTGGCTGTGCTTAGGG This study 
Italic underlined letters designate restriction enzyme sites for SphI and BamHI in F1 and F3 primers, and 
HindIII in F2 and F4 primers. 
 
The PCR product was then electrophoresed in a 1% gel to confirm 1575 bp long 
product, which was subsequently gel-excised and purified by Genejet gel extraction kit 
(Thermo Fisher Scientific). The purified PCR product was digested with SphI and 
HindIII enzymes and cloned into the SphI and HindIII sites of linearized 3429 bp 
fragment of pQE30 plasmid vector (Addgene) in frame with the 6X-His gene using 
T4DNA ligase (Thermo Fisher Scientific) (Figure 4-2A). The product was named as 
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pQE30-F8b-SK. To express the fiber-knob recombinant protein, which represents the 
head of the FAdV-8b-SK fiber, a 453 bp long DNA sequence of fiber gene coding 
approximately 15 kDa protein, was amplified from nucleotide position 1138-1575 in the 
fiber gene. The PCR was performed using cycling conditions similar to that of fiber gene 
with primers F3 and F4 (Table 4-1). The PCR product of the fiber-knob was digested 
with BamHI and HindIII and cloned into BamHI and HindIII sites of linearized 3423 bp 
fragment of pQE30 plasmid vector. The sequence was cloned in frame with the 6X His 
gene using T4DNA ligase (Thermo Fisher Scientific) (Figure 4-2B) and named as 
pQE30-K8b-SK. 
 
 
 
 
 
 
 
 
 
Figure 4-2: Cloning and expression of recombinant fiber or truncated fiber-knob 
proteins of FAdV-8b-SK. (A) Map of the full-fiber gene cloned in-frame with 6XHis tag 
in pQE30 vector using SphI and HindIII sites. (B) Map of the fiber-knob gene cloned in-
frame with 6XHis tag in pQE30 vector using BamHI and HindIII sites. 
 
4.3.5. Protein expression and purification 
To express the fiber and fiber-knob proteins, M17 E. coli competent cells were 
thawed on ice and transformed using 200 ng of either pQE30 vector, pQE30-F8b-SK or 
pQE30-K8b-SK plasmid DNAs and plated on Luria broth (LB)-ampicillin agar plates and 
incubated at 37 C overnight. Later on, a single colony was transferred into 5 mL of LB-
ampicillin from each plate and incubated at 37 C in a shaking incubator. After 16 h of 
A B kpnI 
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incubation, the broth was transferred into 500 mL of LB-ampicillin. When the OD 
reached 0.6, IPTG (Sigma) was added at a final concentration of 1 mM. After overnight 
induction of protein expression, the cells were centrifuged at 6500 rpm for 20 min. The 
pellets were re-suspended in resuspension buffer (NaH2PO4 (50 mM), NaCl (300 mM) 
and imidazole (10 mM), pH 8) and lysed by lysozyme (10 mg/mL) (Sigma) digestion and 
sonication. The crude-lysate was centrifuged at 10,000 g for 30 min at 4 C. The 
supernatant was discarded, and the pellet was stirred in resuspension buffer for 30 min 
and centrifuged as described above. Following centrifugation, the pellet was dissolved by 
addition of 2 mL binding buffer (resuspension buffer with 8 M urea) per gram of the 
pellet which was stirred for 60 min. The resuspended pellet was centrifugation at 10,000 
g for 20 min at 20 C, and the supernatant was collected. The supernatant was used to 
purify the fiber and fiber-knob proteins by affinity column chromatography using 
ProfinityTM IMAC Nickel Charged Resins (Bio-Rad Laboratories Inc.) as per the 
manufacturer’s protocol. The purified proteins were dialyzed in 10 mM Tris-HCl (pH 8), 
three times, for 8 h each and concentrated using Amicon ultra centrifugal units with 
ultracell-10 membrane (Millipore). The protein concentrations were measured by 
Bradford assay.  
 
4.3.6. Coomassie blue staining and Western blotting 
To check for proper expression and purity of the fiber and fiber-knob proteins, 
sodium dodecyl polyacrylamide gel electrophoresis (SDS-PAGE) and Coomassie blue 
staining was performed. Briefly, the proteins were separated on 10% polyacrylamide gel. 
The electrophoresed proteins were stained with Coomassie blue for 45 min and destained 
using a destaining solution. Simultaneously, proteins on another set of gels were 
transferred onto a nitrocellulose membrane (Bio-Rad Laboratories Inc.) in a cold chamber 
and Western blot was performed. In short, the membranes were blocked with 5% BSA in 
TBST for 1 h. The membranes were washed with TBST three times for 10 min each. 
Membranes were incubated with anti-6X His epitope- tag monoclonal antibody (Life 
Technologies) for 1 h. Following incubation, the membranes were washed like previous 
step and incubated with AP-conjugated goat anti-mouse IgG secondary antibody (Life 
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Technologies) for 1 h. Finally, the membranes were washed and developed with 
NBT/BCIP substrate (Sigma).  
 
4.3.7. Preparation of FAdV-8b-SK challenge virus 
FAdV-8b-SK infected liver tissues from previous studies were macerated in 
mortar with pestle and minimal essential media was added to make 40% liver 
homogenate. The homogenate was freeze-thawed four times to release the virus particles 
from the cells and then centrifuged at 6000 rpm for 30 min at 10 C in a high-speed 
centrifuge (Thermo Fisher Scientific). The supernatant was collected and filter sterilized 
by passing through 0.22 m filter (Cameo, Maine Manufacturing, LLC, USA). The 
filtrate was titrated and stored at -80 C. 
 
4.3.8. Broiler breeder vaccination 
Day old broiler breeders (Aviagen, Huntsville, AL) were reared in the Animal 
Care Unit of the Western College of Veterinary Medicine as per Aviagen guidelines. The 
animal experiments were conducted following the approved protocols from Animal 
Research Ethics Board of University of Saskatchewan. At the 30 weeks of age, the broiler 
breeders were randomly divided into 4 groups (n=20 birds/group). Before vaccination, 
blood samples at 0 days of age were collected from each group. Each of the three 
principle groups received FAdV-8b-SK VLPs, FAdV-8b-SK fiber or FAdV-8b-SK fiber-
knob protein (50 µg/bird) with 20% Emulsigen-D (MVP Technologies) intramuscularly 
in the pectoral muscle. The fourth group was kept as unvaccinated control. Each group 
was boosted with the same dose of the particular vaccine at 21 days after the primary 
vaccination. To determine serum-neutralizing antibodies, sera samples (n=10) were 
collected at 14, 21, 28, 35 and 60 dpv for serum neutralization test. In addition, peripheral 
blood mononuclear cells were collected at 21 days after primary vaccination and 4 day 
following booster vaccination (day 25) to measure the CMI response.  
 
4.3.9. Progeny challenge 
Eggs were collected from broiler breeders 3 wk following the booster vaccination, 
which were subsequently hatched (n=30/group) and kept in a single pen for challenge 
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protection studies. Broiler progenies were bled at 13 dph to test for MtAbs against 
FAdVs. At 14 dph, the progenies were challenged with 1x107 TCID50 of FAdV-8b-SK 
per bird to study the immunoprotective ability of vaccine candidates. Cloacal swabs 
(n=5) were collected from all the groups prior to FAdV challenge (0 day) and at 3, 7 and 
10 dpi to determine fecal shedding of FAdV. Liver samples were collected from dead, 
sick (following euthanasia), or clinically healthy birds (at the end of experiment) and 
fixed in 10% neutral buffered formalin for histopathological examination.  
 
4.3.10. Virus isolation from cloacal swabs  
Cloacal swabs were collected with dry cotton swabs (Starplex) and weighted 
before placing in 1 mL Tryptose broth (TB) (Sigma). TB was supplemented with 1:100 
antibiotic-antimycotic solution (1 mL/100 mL) (Gibco). The swabs in TB were vortexed 
for 15 sec and centrifuged at 13000 rpm for 3 min. The supernatant from the cloacal swab 
was filter sterilized using 0.22 m filter (Cameo, Maine Manufacturing LLC, USA). The 
filtrate was transferred into a 96 well plate in triplicate at 1:10 dilution for virus isolation 
and titration. 
 
4.3.11. Measurement of serum IgY antibodies 
Serum IgY was determined by direct ELISA as described in the previous chapter. 
Briefly, polystyrene plates were coated with purified FAdV-8b-SK capsid protein 
(purified from FAdV infected cells by CsCl gradient method) with coating buffer (R&D 
Systems, Minneapolis, MN) at a concentration of 7.5 µg/mL and incubated overnight at 4 
C. The plates were blocked with TBST (1X PBS+0.05% tween-20+2.5% bovine serum 
albumin, pH 7.6) for 1.5 h at room temperature. The plates were then washed two times 
with 1X wash buffer (R&D Systems, Minneapolis, MN) and incubated with 1:100 diluted 
sera samples in duplicate for 1.5 h at room temperature. Following washing, anti-FAdV-
8b-SK IgY antibodies were detected by incubating plates with goat-anti-chicken IgY–AP 
conjugate (Thermo Fisher Scientific, Waltham, MA) for 1.5 h at room temperature. After 
washing with wash buffer, the plates were developed with 100 µL of ready to use p-
nitrophenyl phosphate liquid substrate (Sigma Chemical Co., St. Louis, MO) for 10 min 
at room temperature. The sample absorbance was measured at an optical density (OD) of 
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405 nm in the spectrophotometer (Molecular Devices, Sunnyvale, CA). Positive and 
negative control sera and blank wells with no sera were used as controls. 
 
4.3.12. Measurement of neutralizing antibodies against fowl adenovirus 
VNT was performed in LMH cells with a few modifications to the protocol 
described by Gunes et al. (2012) [270] Serum samples were heat inactivated at 56 C for 
30 min. The samples were serially diluted 2-fold in 96 well plates in triplicates with 
diluent (DMEM-12 containing gentamicin @ 1:1000). 200 TCID50 of FAdV-8b-SK was 
added into each well and the serum-virus mixture was incubated for 1 hr at 37 C with 5% 
CO2. The mixture was then transferred to freshly split cells in 96 well plates (5x104 
cells/well) starting from the highest dilution. Subsequently, the plates were incubated at 
37 C with 5% CO2 and results were read on the day 7.  
 
4.3.13. Quantification of CD4+ and CD8+ T-cells in peripheral blood 
mononuclear cells  
Blood samples were collected in heparinized tubes and diluted 1:1 with 1X PBS 
(pH7.6). 1 mL of diluted blood was layered on histopaque (Gibco) and spun at 2000 rpm 
for 20 min in tabletop centrifuge. PBMC were separated and washed two times with 500 
L of 1X PBS. The cells were incubated with mouse anti-chicken CD4 PE and mouse 
anti-chicken CD8a FITC monoclonal antibodies (1:50 dilution in 1X PBS) (Southern 
Biotech) for 30 min on ice. The cells were washed twice, re-suspended in 400 L of PBS 
and read using a flow cytometer (Beckman coulter) to quantify the lymphocytes. The 
CD4+: CD8+ T-cell ratio was determined by using FlowJo software (Treestar). 
 
4.3.14. Statistical analysis 
The statistical analysis was performed using Prism7 (Graph Pad, Inc, San Diego, 
USA). The survival analysis was performed by Mantel-Cox (Log-rank) test and Student 
T-test with Welch’s correction was used to compare neutralizing antibody responses and 
CD8+ T-cell responses between the vaccine groups. The level of significance (α) was kept 
at 0.05. 
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4.4. Results  
4.4.1. Analysis of purified 6XHis tagged fiber and fiber-knob proteins 
Expected bands of 58 kDa and 15 kDa were detected in purified fiber and fiber-
knob proteins by SDS-PAGE/Coomassie blue staining (Figure 4-3A), respectively and 
their specificity was confirmed by western blot (Figure 4-3B). 
 
 
 
 
 
 
Figure 4-3: SDS-PAGE, Coomassie blue staining and western blot of fiber and fiber-
knob proteins of FAdV-8b-SK. (A) Molecular weight marker is indicated in the left side 
in KDa. (B) Fiber and fiber-knob proteins were detected by using anti-HIS tag 
monoclonal antibodies. Molecular weight marker is indicated on the left side in KDa. 
Lane 1 & 4 = marker, Lane = 2 & 5, fiber protein and Lane 3 & 6 = fiber-knob protein. 
 
4.4.2. Isolation and examination of mature FAdV-8b-SK virion and purified 
Virus-like particles 
To separate the FAdV-8b-SK VLPs from mature virions, the infected cell lysates 
was spun in Cesium chloride density gradient in ultracentrifuge. As shown in Figure 4-4 
A, specific bands of FAdV-8b-SK VLPs, and mature virions were efficiently separated 
after centrifugation. Electron microscopy was performed for confirmation and as shown 
in Figure 4-4B. Pure VLPs in the capsid band and matured virions  in the mature virus 
band were detected Figure 4-4C. In addition, major structural proteins were identified in 
the VLPs by Coommassie blue staining (Figure 4-4D). Due to the lack of specific anti- 
FAdV monoclonal antibodies for western blot, the protein size was estimated based on 
A B 
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predicted size of protein from FAdV-8b virus. The purified VLPs did not cause any 
cytopathic effects in LMH cells on two continuous passages. 
 
 
 
 
 
 
Figure 4-4: Purification of FAdV-8b-SK VLPs. (A) CsCl density gradient purification 
of mature virions and VLPs of FAdV-8b-SK. (B) & (C), Transmission electron 
microscopy of VLPs and mature virion fractions of FAdV-8b-SK. (D) SDS-PAGE and 
Coomassie blue staining of the capsid proteins. Some of the structural proteins are 
indicated on the right based on their molecular weight. Molecular weight markers are 
indicated on the left of the panel. 
 
4.4.3. Serum IgY and neutralizing antibodies against FAdV following broiler 
breeder vaccination  
To examine the immunogenicity of FAdV-8b-SK VLPs, fiber and fiber-knob, 
serum samples were subjected to ELISA and neutralization testing. Mean log10 IgY 
antibody levels in groups vaccinated with fiber, fiber-knob and VLPs vaccinated groups 
at 14 dpv were 3.6 log10±0.35, 4.0 log10±0.07 and 4.0 log10±0.07, respectively (Figure 
B 
C D 
A 
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B A 
4-5A) IgY response peaked in VLP group at 35 dpv with mean IgY level of 3.9 
log10±0.22. Mean IgY levels were similar in all the groups at 60 dpv.  
To determine the neutralizing ability of these IgY antibodies, the serum samples 
were analyzed in a VNT. Serum neutralizing antibodies were first detected at 14 dpv with 
mean titers of 2.47 log100.16, 1.82 log100.23 and 2.75 log100.25 in fiber, fiber-knob 
and VLPs vaccinated groups, respectively (Figure 4-5B). Only 70%, and 10% of the 
tested samples had detectable neutralizing antibodies response at 14 dpv in fiber and 
fiber-knob vaccinated groups, whereas 100% birds had serum-neutralizing antibodies in 
the VLPs vaccinated group. Mean log10 serum neutralizing antibody levels in breeders 
vaccinated with VLPs were significantly higher than fiber or fiber-knob vaccinated 
breeders at all the sampling time points (P0.05) 
 The neutralizing antibody levels peaked at 35 dpv in fiber and VLPs vaccinated 
groups with mean antibody levels of 3.0 log10±0.24 and 3.71 log10±0.31, respectively. 
The mean serum neutralizing antibody titers in fiber-knob vaccinated group remained 
low at all the time points and ranged between 1.82 log10±0.23 to 2.3 log10±0.02 
throughout the experiment. The mean neutralizing antibody levels declined to a lower 
level in all the groups at 60 dpv. 
 
Figure 4-5: Serum IgY and neutralizing antibody levels in broiler breeders at 
various ages. (A) IgY antibody levels (Mean log10SD) in broiler breeders vaccinated 
with fiber, fiber-knob or whole capsid proteins at 7, 14, 28, 35 and 60 days post-
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vaccination. (B) Mean serum neutralizing antibody titer in broiler breeders immunized 
with the indicated proteins at 7, 14, 28, 35 and 60 days post-vaccination. 
 
4.4.4. CD4+ and CD8+ T-cell ratio in PBMC following booster vaccination 
Induction of cellular immunity, CD4+ and CD8+ T-cells, were monitored before 
and after booster vaccination. No significant difference was observed in the mean 
CD4+:CD8+ T–cell ratio in any groups before booster vaccination (Figure 4-6). However, 
following booster vaccination, there was a significant proliferation of CD8+ cytotoxic T-
cells in broiler breeders vaccinated with the fiber protein (P<0.05) or VLPs (P<0.05). 
Mean CD4+:CD8+ T–cell ratio lowered from 3.231.35 (before booster) to 1.20.14 
(following booster) in fiber protein vaccinated breeders. Likewise, mean CD4+:CD8+ T–
cell ratio declined from 2.720.72 (before booster) to 1.520.86 (following booster), in 
VLPs vaccinated breeders. In contrast, there was no difference in CD4+:CD8+ T–cell 
ratio between fiber-knob vaccinated and the control group. 
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Figure 4-6: CD4+:CD8+ T-cell ratio in peripheral blood mononuclear cells. CD4+ and 
CD8+ T-cell levels in the peripheral blood mononuclear cells before (at 21 days) and four 
days after booster vaccination of breeders with the indicated vaccines. [(P0.05), 
unpaired student t-test with Welch’s correction] 
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4.4.5. Challenge and protection studies in progenies  
Progenies from broiler breeders that were vaccinated with VLPs had significantly 
higher mean serum neutralizing antibodies (3 log10±0.32) than progenies from broiler 
breeders vaccinated with recombinant fiber protein (2.4 log10±0.15) (P0.05). No serum 
neutralizing antibodies were detected in progenies that originated from either the 
recombinant fiber-knob vaccinated broiler breeders or unvaccinated control breeders 
(Figure 4-7A). A significant survival, following FAdV-8b-SK challenge, was observed in 
the broiler progenies of VLP and recombinant fiber vaccinated breeders (P0.05) 
compared to broiler progenies in the control group (Figure 4-7B). No significant 
difference in the survival was observed between the fiber-knob and the control groups. 
The broiler chickens that died of disease or clinically sick birds that were euthanized 
post-challenge had similar lesions irrespective of the group. Macroscopic lesions were 
severe multifocal necrotizing hepatitis (pale-yellow, swollen and hemorrhagic livers with 
prominent reticular pattern) and multifocal pancreatic necrosis. On microscopic 
examination, multifocal to coalescing areas of necrosis were observed in the livers of the 
dead or clinically sick birds which were characterized by the lysis of hepatocytes with 
fragmentation and karyolysis of nuclei. Hepatocytes adjacent to the necrotic areas were 
degenerated and had karyomegalic nuclei, which were identified as basophilic adenoviral 
inclusion bodies. Pancreatic lesions included necrosis of pancreatic acinar cells and 
basophilic intranuclear inclusions in the adjacent cells.  
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Figure 4-7: Neutralizing antibody levels in broiler progenies and virus challenge. (A) 
Mean neutralizing maternal antibody level in broiler progeny at13 dph from broiler 
breeders immunized with the indicated vaccine antigens. (B) Kaplan-Meier survival 
estimate of broiler progeny following lethal virus challenge with FAdV-8b-SK at 14 dph 
(P<0.05), n=30/group. 
 
4.4.6. Fowl adenovirus shedding following challenge 
FAdV shedding was examined in broiler chickens for 10 dpi following challenge 
with virulent FAdV-8b-SK at 14 days of age. As shown in the Figure 4-8, peak fecal 
FAdV shedding was observed at day 3 with the highest titer in the control group (8.69 
log101.12), followed by knob (8.56 log101.01), and fiber group (7.1 log101.37), but no 
shedding was detected in VLPs group. The shedding declined by approximately one log 
at 7 dpi in fiber and fiber-knob groups, but not in the control group. At 7 dpi, FAdV 
shedding was also observed for the first time in the VLPs group. The quantity of the virus 
shed by the broilers in VLPs group was lowest (4.46 log102.03), followed by the fiber 
(6.16 log101.38), fiber-knob (7.36 log101.38) and control (8.49 log100.74), 
respectively. No fecal FAdV shedding was detected at 10 dpi in any of the groups. 
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Figure 4-8: Fecal shedding by broiler progeny following FAdV-8b-SK challenge. 
Fecal shedding (Mean log10SD) of FAdV-8b-SK in broiler chickens following FAdV-
8b-SK challenge at 14 days of age. 
 
4.5. Discussion 
Broiler breeder vaccination is widely practiced in the industry to protect broiler 
chicks from infectious diseases in their first few weeks of life [358]. However, it is not 
known if subunit vaccines can be used as broiler breeder vaccines against IBH. To our 
knowledge, this is the first study to evaluate the immunogenicity of FAdV-8b-SK VLP, 
recombinant fiber, or fiber-knob vaccines in broiler breeders and assess the protective 
efficacy of transferred MtAb by progeny challenge.  
FAdV-8b-SK VLPs, fiber and fiber-knob proteins were immunogenic as 
demonstrated by presence of IgY antibodies. We detected a similar level of IgY 
antibodies in all the groups at all the times. The amount of IgY levels might be associated 
with either limited quantity of antigen coating on ELISA plates or high level of IgY 
antibody level in sera which could saturate wells. Hence, we did not see a difference 
among antibody levels. The ELISA test conditions were optimum since negative samples 
had OD values similar to blank samples. FAdV-8b-SK VLP and FAdV-8b-SK fiber 
subunit vaccines induced significant NAb responses in broiler breeders. A very high level 
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of NAb observed in FAdV-8b-SK VLP group was likely associated with hexon and 
penton proteins which is supported by previous studies that reported neutralizing nature 
of anti-hexon and anti-penton antibodies [100, 101, 306]. The FAdV-8b-SK fiber-knob 
subunit vaccine, although it induced a very high level of IgY in broiler breeders, the 
neutralizing activity of these antibodies was either minimal or undetectable. The lack of 
neutralizing activity of antibodies to the fiber-knob protein in our study could be 
explained by the absence of amino acid repeats critical to the tertiary structure of the fiber 
knob [359]. 
In addition to humoral immunity, cell-mediated immune responses play a 
significant role in controlling virus infections in chickens [360]. Therefore, we next 
investigated whether such subunit vaccines can induce cellular immunity in vaccinated 
birds. After the vaccination or pathogenic challenge, primary cytotoxic T-cell-mediated 
immunity develops within a week after the antigenic stimulation. About 3-weeks later 
memory cytotoxic T-cells robustly proliferate on secondary stimulation and provide 
protection against the reinfection [201]. Therefore, in this study, we examined the 
secondary cytotoxic T-cell response. Just before booster/secondary vaccination with the 
FAdV-8b VLPs, fiber and fiber-knob, we quantified the CD4+:CD8+ T-cell ratio in 
PBMC and then again four days after boosting. We did not find any significant change in 
the CD4+:CD8+ T-cell ratio in fiber-knob vaccinated breeders and unvaccinated controls. 
However, a significant increase (P0.05) in the level of cytotoxic CD8+ T-cells was 
observed following boosting with FAdV-8b-SK VLPs, and FAdV-8b-SK fiber vaccines; 
suggesting these vaccines were able to induce memory cytotoxic T-cell immunity. There 
are no such studies with FAdVs available in the literature to compare. Thus, our results 
clearly demonstrated that VLP, and subunit vaccines can induce potent humoral and 
cellular immunity in broiler breeders.  
We next investigated, whether the antibodies induced through broiler breeder 
vaccination with FAdV-8b-SK VLPs, FAdV-8b-SK fiber, and FAdV-8b-SK fiber-knob 
vaccines are transferred to their progeny and if they provide protection against FAdV-8b-
SK virus. We tested neutralizing MtAb levels in progeny hatched from all groups at 13 
dph. The neutralizing MtAb levels at 13 days of age, constituted approximately 
28.49.9% of serum neutralizing antibodies of their parents vaccinated with FAdV-8b-
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SK VLP or FAdV-8b-SK fiber vaccine at 35 dpv. Our results are supported by previous 
studies that demonstrated approximately 25.621.42 to 36.064.34% or 27-31% of MtAb 
(IgY) transfer to eggs/progeny following vaccination of hens with Salmonella [361], 
NDV and infectious bronchitis virus vaccines [358], respectively. However, like 
unvaccinated control breeders, we could not detect neutralizing MtAb in progeny hatched 
from FAdV-8b-SK fiber-knob vaccinated broiler breeders. This observation is most 
likely partial or complete lack of neutralizing antibodies in broiler breeders injected with 
fiber-knob protein or rapid depletion of maternal antibodies post-hatch. 
To test the efficacy of MtAb in the prevention of clinical disease, we performed 
progeny challenge studies at 14 dph, which is the most likely age of disease occurrence in 
the field outbreaks. Our results demonstrated 100% protection of progeny (P0.05) 
against FAdV-8b-SK challenge when breeders were vaccinated with FAdV-8b-SK VLPs. 
Similarly, 82.7% survival (P0.05) was observed in progeny hatched from broiler 
breeders immunized with FAdV-8b-SK fiber protein. Few progeny in FAdV-8b-SK fiber 
group died following FAdV-8b-SK challenge. Retrospective analysis of their sera 
samples showed that these dead chicks did not have detectable levels (2.0 log10) of MtAb 
at 13 dph. Previous studies have also reported similar observations [43]. This could be 
explained by the progressive decline of maternal antibodies [362] or lower level of serum 
neutralizing antibodies in breeders at the time of egg collection. Like unimmunized 
controls, progeny hatched from FAdV-8b-SK fiber-knob vaccinated breeders were not 
protected against FAdV-8b-SK challenge, which is an expected result as no MtAb were 
detected before challenge.  
Fecal shedding is an important parameter, which reflects the efficacy of viral 
vaccines. Fecal shedding was monitored to evaluate the efficacy of MtAb in the 
prevention of shedding following intramuscular challenge with virulent FAdV-8b-SK. 
Fecal shedding was observed in progeny post-challenge despite having maternal 
antibodies. However, it is noteworthy that it was delayed in progeny hatched from FAdV-
8b-SK VLP vaccinated breeders compared to those of other groups that who shed the 
virus from the beginning. The early high level of antibodies and synergistic activity of 
anti-fiber, anti-hexon, and anti-penton antibodies induced by FAdV-8b-SK VLPs might 
explain the delayed occurrence of shedding. Synergism between anti-fiber and anti-
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penton neutralizing antibodies has been reported to inactivate adenovirus in humans 
following HAdV-5 vector therapy [101]. Furthermore, delayed appearance of fecal 
shedding in the progeny of the VLP group was likely due to declining MtAb titers in the 
progeny, which is a common phenomenon observed in broiler chickens. Failure to 
prevent shedding in the first week following virus challenge was reported by Schachner 
et al. (2014) [43] and Schonewille et al. (2010) [260], in SPF chicks immunized with 
recombinant fiber antigens or attenuated FAdV-4 virus. It might also be likely that the 
virus was neutralized in the blood, but replication was not prevented in the intestinal 
epithelial cells. Enterocytes in the region of the cecal tonsils are a common site of FAdV 
replication in chickens [363]. Infectious virus was not detected in any of the broiler 
groups ten days post-challenge. Similarly, Schonewille et al. (2010) failed to isolate 
infectious virus after one week following infection of SPF chicks with cell culture 
attenuated FAdV-4 [260].  
 
4.6. Conclusions  
In summary, we have demonstrated that immunization of broiler breeders with 
VLPs or subunit vaccines composed of the fiber protein of FAdV-8b-SK induced 
neutralizing antibodies and cytotoxic T-cell responses in breeders as well as successfully 
prevented clinical disease in progeny through MtAb transfer. Collectively, our data 
provide evidence supporting the potential of subunit vaccines in broiler breeder 
vaccination programs and may have implications for vaccine development against IBH. 
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CHAPTER 5: DISCUSSION AND CONCLUSIONS 
 
IBH is an acute viral disease of broiler chickens characterized by hepatic necrosis 
and death in 1 to 5 week-old broiler chickens. IBH has been reported in pullets. IBH is 
characterized by a sudden increase in flock mortality 3 to 4 days post-infection which 
then subsides 6 days post-infection onwards. The percentage of mortality due to IBH 
outbreaks are highly variable but may reach as high as 30%. Pale-yellow, necrotic and 
hemorrhagic livers with basophilic intranuclear inclusion bodies in hepatocytes are the 
characteristic lesions of IBH [189]. IBH is a primary disease of broilers, however, it is 
not uncommon to see it as an opportunistic infection in immunosuppressed chickens 
[161]. IBH is caused by FAdVs belonging to five species (A to E). These five species of 
FADVs contain twelve serotypes (-1 to -7, -8a, -8b, -9 to -11). FAdV-2, -7, -8a, -8b and -
11 are associated with outbreaks of IBH worldwide including Canada [3, 211, 214]. IBH 
as a primary disease has been emerging over the last fifteen years in Canada but reasons 
associated with this emergence have not been identified. FAdVs disseminate vertically 
from broiler breeders to their chicks and then horizontally by contaminated feed, water, 
fomites and farm equipment [189]. Therefore, breaking vertical transmission by 
vaccination of broiler breeders is the main disease control strategy.  As there is no 
commercial FAdV vaccine available in Canada, broiler breeder autogenous vaccines are 
commonly used as a preventative measure in endemic areas. Therefore, the goal of this 
project was to develop live, inactivated or subunit vaccines to control IBH and to identify 
an immunogenic and safe adjuvant for an inactivated FAdV vaccine. 
In the second chapter, we have demonstrated the development of a bivalent live 
and inactivated FAdV vaccine to prevent IBH caused by a prevalent serotype of FAdV in 
broiler chickens.  We have also demonstrated the safety and efficacy of a live FAdV 
vaccine in broiler breeders by vaccinating them and challenging their broiler progeny 
with different serotypes of FAdVs. We have further demonstrated that protection of 
broiler progeny against IBH depends on passive transfer of NAbs against FAdVs from 
their broiler breeder parents vaccinated with a live or inactivated FAdV vaccine. 
Live FAdV vaccines were previously developed and demonstrated the ability to 
protect broiler chickens against HHS [260, 300] and IBH [229]. Although vaccination of 
  
98 
  
broiler breeders with a wild-type live FAdV has been reported previously [229], FAdV 
shedding in broiler breeders was not evaluated in detail. Vaccination of broiler breeders 
during egg production is risky due to the possibility of vertical transmission of FAdVs 
[189]. We were able to demonstrate vertical transmission of a wild-type FAdV (FAdV-
8b-SK) from broiler breeders to their progeny for a period of 7 days if broiler breeders 
were vaccinated with live FAdV-8b-SK while in egg production [272, 273].  We were 
able to demonstrate discontinuation of vertical transmission of FAdV-8b-SK 2 weeks 
following live FAdV vaccination in broiler breeders due to production of NAb against 
FAdV.  We have also found that FAdV shedding in feces continues for 3 weeks 
following vaccination of broiler breeders with a live FAdV vaccine. Hence, we concluded 
that live wild-type FAdVs can be safely included in a broiler breeder vaccination 
program by vaccinating broiler breeders at 16 weeks of age, well before they begin egg 
production. 
NAbs neutralize FAdVs and protect broiler progeny from clinical disease of IBH 
if there is an adequate amount of MtAb against FAdV in the progeny. We were able to 
demonstrate protection of broiler chickens against IBH by vaccinating broiler breeders 
with a live FAdV vaccine containing 1x104 TCID50 of FAdV-8b-SK+FAdV-11-1047 or 
vaccinating broiler breeders twice with 1x106 TCID50 of FAdV-8b-SK+FAdV11-1047.  
We also found that protective NAb titers (i.e. ≥3.0 log10) can be successfully maintained 
in broiler breeders until at least the end of peak egg production either by vaccinating 
broiler breeders with a single dose of the live FAdV vaccine or with two doses of the 
inactivated FAdV vaccine. We were able to demonstrate significant protection (i.e. 98-
100%) of broiler chickens against homologous and heterologous FAdV challenge 
(FAdV-2-685, FAdV-7-x-11a like and FAdV-8a-TR59) by vaccinating their parents with 
a bivalent FAdV vaccine (FAdV-8b-SK+FAdV-11-1047). Hence it was concluded that 
both the bivalent live or inactivated FAdV vaccine were equally efficacious in protecting 
broiler chickens against IBH. Since we have demonstrated the above observations in a 
large-scale efficacy experiment, potential commercial companies have the ability to 
access and use our data for commercialization of these vaccine candidates to prevent IBH 
in broiler chickens in Canada. 
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We have seen a remarkable humoral immune response (NAb) to inactivated 
bivalent FAdV antigens when Emulsigen-D was included as a vaccine adjuvant. 
However, Emulsigen-D, as do other mineral oils, causes severe muscle necrosis and 
inflammation at the injection site [318]. Therefore, to make the inactivated FAdV vaccine 
safe and less irritating, we have analyzed the cellular and humoral immune responses of 
the inactivated FAdV-8b-SK vaccine adjuvanted with CpG-ODNs (Chapter 3). CpG-
ODN is a potent immunostimulant of mammalian and avian immune systems [321, 336]. 
It causes a transient, moderate inflammatory reaction without tissue necrosis at the 
injection site in chickens [318, 342].  The immune response due to CpG-ODN as an 
adjuvant with FAdV antigens was polarized towards Th-1 type immunity (IFN-γ, CD4+ 
and CD8+ T-cells) while the immune response due to Emulsigen-D with FAdV antigens 
was polarized towards Th-2 type immunity (IL-4 and CD+ T-cells). Moreover, CpG-
ODN enhanced cytotoxic T-cell memory responses to the FAdV vaccine, which may be 
beneficial in protection against FAdVs in broiler breeders during the entire egg 
production period. Our data suggests that CpG-ODN can provide an alternative to 
mineral oil emulsions to improve the safety and quality of immune responses to 
inactivated FAdV vaccines. 
It can be challenging to propagate viruses large-scale in in vitro systems for 
making inactivated vaccines. Alternatively, subunit antigens can be prepared for such 
pathogens. Several studies have demonstrated the efficacy of subunit avian adenoviral 
vaccines against egg drop syndrome virus [181], hemorrhagic enteritis virus [309] and 
FAdV-4 [43]. In chapter 4, we demonstrated the construction of fiber and VLP subunit 
vaccines for FAdV-8b-SK. Although several FAdV proteins such as fiber, penton, hexon 
or 100K can be used as vaccine candidates [43, 305], fiber protein has been presented as 
the best option because of its immunogenicity [43]. Adenoviral fibers interact with 
cellular receptors [54] hence antibodies against fiber proteins can neutralize FAdV 
infections [181]. We have studied truncated fiber protein (fiber-knob) as suggested by 
Figerut et al. (2003) [181] to improve the yield of the protein in our studies. We 
measured the vaccine efficacy by assessing passive transfer of MtAb to broiler chickens. 
We demonstrated significant protection [i.e. 82.7% (fiber vaccine) to 100% (VLP 
vaccine) (P<0.05)] in broiler chickens against a lethal challenge of FAdV when NAb 
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were at ≥3.0 log10 in broiler breeders. This NAb titer against FAdV peaked at 6 weeks 
post-vaccination.  We also demonstrated that FAdV-8b-SK fiber and VLPs induce a 
strong cytotoxic T-cell response in broiler breeders. Our study provided novel 
information that FAdV subunit vaccines can be used as a broiler breeder vaccine to 
prevent IBH in their broiler progeny. 
We have demonstrated conventional vaccines (live and inactivated FAdV 
vaccines), subunit vaccines against FAdV and efficacy of different adjuvants designed for 
FAdV vaccines in broiler breeders to prevent IBH in their progeny. Based on results of 
this study we can design and investigate possibility of controlling IBH in broiler in 
different geographical locations by using multiple serotypes of FAdV as a vaccine. In 
addition to different combinations of FAdVs in a vaccine, immune responses of broiler 
breeders against FAdVs can be improved by different adjuvants. It has been 
demonstrated previously that tissue reactions due to Emulsigen-D can be reduce by 
vaccines containing CpG-ODN as an adjuvant and this can be used in FAdV vaccination 
in broiler breeders to reduce condemnations at processing.  Furthermore, the advantages 
of recombinant DNA technology can be harnessed in developing VLPs vaccines against 
IBH. Recombinant DNA technology can be used to develop fiber gene-based vectored 
vaccines. Since fiber protein encodes epitopes for both cellular and humoral immunity, 
fiber protein can activate both cellular and humoral immunity to control FAdV infections 
efficiently. Utility of fiber protein to control IBH can be achieved by producing fiber 
protein in large quantities using DNA technology. Furthermore, immunogenic tetramers 
recognizing T-cell epitopes of fiber proteins can be developed to further characterize T-
cell responses against IBH. 
Overall this project demonstrated conventional and new control strategies for the 
prevention of IBH in broiler chickens.  We also demonstrated the safety and efficacy of 
live, inactivated and subunit FAdV vaccines. We were also able to demonstrate that 
FAdV-8b-SK fiber has the capability of inducing NAb production and induction of CD8+ 
T-cells which may be important in immune memory. This information can be exploited 
by in ovo vaccination technology by using FAdV fiber as a subunit or vectored vaccine; 
hence offering the potential of activating both cellular and adaptive immunity of broiler 
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chickens against FAdV. The results of this study will help in designing FAdV control 
strategies in broiler chickens in Canada. 
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